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NASH limits anti-tumour surveillance in 
immunotherapy-treated HCC
 
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic 
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been 
approved for treating HCC, but biomarker-based stratification of patients for 
optimal response to therapy is an unmet need6,7. Here we report the progressive 
accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in 
NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic 
immunotherapy targeted at programmed death-1 (PD1) expanded activated 
CD8+PD1+ T cells within tumours but did not lead to tumour regression, which 
indicates that tumour immune surveillance was impaired. When given 
prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–
HCC and in the number and size of tumour nodules, which correlated with increased 
hepatic CD8+PD1+CXCR6+, TOX+, and TNF+ T cells. The increase in HCC triggered by 
anti-PD1 treatment was prevented by depletion of CD8+ T cells or TNF neutralization, 
suggesting that CD8+ T cells help to induce NASH–HCC, rather than invigorating or 
executing immune surveillance. We found similar phenotypic and functional profiles 
in hepatic CD8+PD1+ T cells from humans with NAFLD or NASH. A meta-analysis of 
three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed 
death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that 
immune therapy did not improve survival in patients with non-viral HCC. In two 
additional cohorts, patients with NASH-driven HCC who received anti-PD1 or 
anti-PDL1 treatment showed reduced overall survival compared to patients with 
other aetiologies. Collectively, these data show that non-viral HCC, and particularly 
NASH–HCC, might be less responsive to immunotherapy, probably owing to 
NASH-related aberrant T cell activation causing tissue damage that leads to impaired 
immune surveillance. Our data provide a rationale for stratification of patients with 
HCC according to underlying aetiology in studies of immunotherapy as a primary or 
adjuvant treatment.
Potentially curative treatments for HCC, such as liver transplantation, 
tumour resection, or ablation, are limited to early-stage tumours1,2. 
Multikinase inhibitors and anti-VEGF-R2 antibodies have been approved 
for use in advanced HCC1,2. Immunotherapy, which is thought to activate 
T cells or reinvigorate immune surveillance against cancer, showed 
response rates of 15–30% in patients with HCC5,8–11. Nivolumab and 
pembrolizumab (PD1-directed antibodies) have been approved for 
treatment of HCC3,4, although phase III trials failed to reach their pri-
mary endpoints to increase survival1,10,11. A combination of atezolizumab 
(anti-PDL1) and bevacizumab (anti-VEGF) demonstrated increased 
overall and progression-free survival in a phase III trial, making it a 
first-line treatment for advanced HCC5. The efficacy of immunotherapy 
might be affected by different underlying HCC aetiologies, with diverse 
hepatic environments distinctly regulating HCC induction and immune 
responses6. Hence, we lack biomarkers that correlate with treatment 
response to allow patient stratification12,13. Non-alcoholic fatty liver 
disease (NAFLD) is an HCC-causing condition that affects more than 
200 million people worldwide14. Approximately 10–20% of individuals 
with NAFLD progress over time from steatosis to NASH14. Innate and 
adaptive immune-cell activation15–17, in combination with increased 
metabolites and endoplasmic reticulum stress16,18, are believed to lead 
to a cycle of hepatic necro-inflammation and regeneration that poten-
tially leads to HCC19–21. NASH has become an emerging risk factor for 
HCC1,14,19, which led us to investigate the effects of immunotherapy in 
NASH–HCC22–24.
Hepatic CD8+PD1+ T cells increase in NASH
We fed mice with diets that cause progressive liver damage and NASH 
over 3–12 months (Extended Data Fig. 1a–c), accompanied by an 
increase in the frequency of activated CD8+ T cells expressing CD69, 
CD44 and PD1 (Extended Data Fig. 1d–g). Single-cell mapping of leu-
kocytes showed altered immune-cell compositions in mice with NASH 
(Extended Data Fig. 1h, i) with strongly increased numbers of CD8+PD1+ 
cells (Fig. 1a, b, Extended Data Fig. 1j–m, o). Similarly, elevated CD8+ and 
PD1+ cells were found in a genetic mouse model of NASH17 (Extended 
Data Fig. 1n). Messenger RNA in situ hybridization and immunohisto-
chemistry showed that increasing PDL1 expression in hepatocytes and 
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non-parenchymal cells correlated with the severity of NASH (Extended 
Data Fig. 1p). Mass spectrometric characterization of CD8+PD1+ T cells 
from NASH-affected livers indicated enrichment in pathways involved 
in ongoing T cell activation and differentiation, TNF signalling, and nat-
ural killer (NK) cell-like cytotoxicity (Fig. 1c). Single-cell RNA sequencing 
(scRNA-seq) of cells expressing T cell receptor β-chains (TCRβ) from the 
livers of mice with NASH showed that CD8+ T cells had gene expression 
profiles related to cytotoxicity and effector-function (for example, 
Gzmk and Gzmm) and inflammation markers (for example, Ccl3) with 
elevated exhaustion traits (for example, Pdcd1 and Tox) (Fig. 1d, e). 
RNA-velocity analyses demonstrated enhanced transcriptional activ-
ity and differentiation from Sell-expressing CD8+ to CD8+PD1+ T cells 
(Extended Data Fig. 1q), indicating local differentiation. Thus, mice 
with NASH have increased hepatic abundance of CD8+PD1+ T cells with 
features of exhaustion and effector functions.
The high numbers of T cells in NASH suggest that anti-PD1-targeted 
immunotherapy may serve as an efficient therapy for NASH–HCC. 
Thirty per cent of C57BL/6 mice fed a choline-deficient high-fat diet 
(CD-HFD) for 13 months developed liver tumours with a similar load 
of genetic alterations to human NAFLD–HCC or NASH–HCC (Extended 
Data Fig. 2a, b). NASH mice bearing HCC (identified using MRI) were 
allocated to anti-PD1 immunotherapy or control arms (Fig. 1f). None of 
the pre-existing liver tumours regressed in response to anti-PD1 ther-
apy (Fig. 1g, h, Extended Data Fig. 2c). Rather, we observed increased 
fibrosis, unchanged liver damage, slightly increased incidence of liver 
cancer and unaltered tumour loads and sizes after anti-PD1 treatment 
(Extended Data Fig. 2 d–h). In anti-PD1-treated mice, liver tumour tissue 
contained increased numbers of CD8+/PD1+ T cells and high levels of 
cells expressing Cxcr6 or Tnf mRNA (Extended Data Fig. 2i–n). We found 
no regression of NASH-induced liver tumours upon anti-PDL1 immu-
notherapy (Extended Data Fig. 3a–f). By contrast, other (non-NASH) 
mouse models of liver cancer (with or without concomitant damage) 
reacted to PD1 immunotherapy with tumour regression25, suggesting 
that lack of response to immunotherapy was associated specifically 
with NASH–HCC (Extended Data Fig. 3g–i). Thus, NASH precluded 
efficient anti-tumour surveillance in the context of HCC immunother-
apy. Similarly, impaired immunotherapy has been described in mouse 
models with NASH and secondary liver cancer25,26.
CD8+ T cells promote HCC in NASH
As CD8+PD1+ T cells failed to execute effective immune surveillance, 
but rather showed tissue-damaging potential, we reasoned that CD8+ 
T cells might be involved in promoting NASH–HCC. We depleted 
CD8+ T cells in a preventive setting in mice with NASH but without 
liver cancer (CD-HFD fed for 10 months). CD8+ T cell depletion sig-
nificantly decreased liver damage and the incidence of HCC in these 
mice (Fig. 2i, Extended Data Fig. 4a–j, n). Similar results were obtained 
after co-depletion of CD8+ and NK1.1+ cells (Fig. 2i, Extended Data 
Fig. 4a–f, n). This suggests that as well as lacking immune surveillance 
functions, liver CD8+ T cells also promote HCC in mice with NASH. 
Next, we investigated the effect of anti-PD1 therapy on HCC devel-
opment in mice with NASH. Anti-PD1 immunotherapy aggravated 
liver damage (Fig. 2g, Extended Data Fig. 7c) and increased hepatic 
CD8+PD1+ T cells, with only minor changes in liver CD4+PD1+ T cells or 
other immune-cell populations (Extended Data Fig. 4a–o). Anti-PD1 
immunotherapy also caused a marked increase in liver-cancer inci-
dence, independent of changes in liver fibrosis (Fig. 2i). Mice lacking 
PD1 (Pdcd1−/−) showed an increase in incidence of, and earlier onset of, 
liver cancer, along with increased liver damage and elevated numbers 
of activated hepatic CD8+ T cells with increased cytokine expression 
(IFNγ, TNF) (Extended Data Fig. 5a–g). In summary, CD8+PD1+ T cells 
triggered the transition to HCC in mice with NASH, probably owing 
to impaired tumour surveillance and enhanced T cell-mediated tis-
sue damage27. Despite a strong increase in CD8+PD1+ T cells within 
tumours, therapeutic PD1- or PDL1-related immunotherapy failed to 
cause tumour regression in NASH–HCC.
We used an immune-mediated cancer field (ICF) gene-expression 
signature associated with the development of human HCC28 to 
understand the tumour-driving mechanisms of anti-PD1 immuno-
therapy. Preventive anti-PD1 treatment was strongly associated with 
the pro-tumorigenic immunosuppressive ICF signature (for exam-
ple, Ifng, Tnf, Stat3, Tgfb1), capturing the traits of T cell exhaustion, 
pro-carcinogenic signalling, and mediators of immune tolerance 
and inhibition. Depletion of CD8+ T cells led to significant down-
regulation of the high-infiltrate ICF signature and diminished TNF 
in non-parenchymal cells (Extended Data Fig. 5h, i). Gene set enrich-
ment analysis (GSEA), mRNA in situ hybridization, and histology of 
tumours developed in NASH mice that were treated prophylactically 
with anti-PD1 corroborated these data, showing increased CD8+ T cell 
abundance and enrichment for genes involved in inflammation-related 
signalling, apoptosis, and TGFβ signalling (Extended Data Fig. 5j–l). 
Anti-PD1 treatment triggered the expression of p62 (Extended Data 
Fig. 5m), which has been shown to drive hepatocarcinogenesis29. Array 
comparative genomic hybridization identified no significant differ-
ences in chromosomal deletions or amplifications between tumours 
from anti-PD1-treated mice or control mice (Extended Data Fig. 5n). In 
summary, hepatic CD8+PD1+ T cells did not cause tumour regression 
during NASH, but rather were linked to HCC development, which was 
enhanced by anti-PD1 immunotherapy.
We next analysed the hepatic T cell compartment for correlations 
with inflammation and hepatocarcinogenesis. Comparison of CD8+PD1+ 
T cells with CD8+ T cells by scRNA-seq showed that the former showed 
higher expression of genes associated with effector function (for exam-
ple, increased Gzma, Gzmb, Gzmk, Prf1; reduced Sell, Klf2), exhaus-
tion (for example, increased Pdcd1, Tox; reduced Il7r, Tcf7) and tissue 
residency (for example, increased Cxcr6, low levels of Ki-67) (Extended 
Data Fig. 6a–c). Notably, there was no difference in the transcriptome 
profiles of CD8+PD1+ T cells in NASH mice after anti-PD1 immunotherapy 
(Extended Data Fig. 6c), indicating that the number of T cells rather than 
their functional properties were changed. RNA-velocity blot analyses 
corroborated these data (Fig. 2a, Extended Data Fig. 6d–f). Similar pat-
terns of markers (for example, IL7r, Sell, Tcf7, Ccl5, Pdcd1, Cxcr6, and 
Rgs1) correlated with latent time and overall transcriptional activity in 
NASH mice that received either treatment (Fig. 2a, b, Extended Data 
Fig. 6e, f). Mass spectrometry-based analyses of CD8+ or CD8+PD1+ 
T cells isolated from NASH mouse livers confirmed these findings 
(Fig. 2c, Extended Data Fig. 6g).
We characterized the transcriptome profiles of PD1+CD8+ T cells 
by uniform manifold approximation and projection (UMAP) analysis 
of high-parametric flow-cytometry data, dissecting the CD8+PD1+ 
and CD8+PD1− subsets (Fig. 2d). This revealed that CD8+PD1+ cells 
expressed high levels of effector (for example, Gzmb, Ifng, Tnf) and 
exhaustion markers (for example, Eomes, Pdcd1, Ki-67low). In particular, 
CD8+PD1+TNF+ cells were more abundant upon anti-PD1 treatment 
(Fig. 2e). Convolutional neural network analysis and manual gat-
ing validated this result (Fig. 2f, Extended Data Fig. 6j, k). CD8+PD1+ 
T cells were non-proliferative in anti-PD1-treated NASH mice; this 
result was supported by in vitro experiments, in which anti-PD1 treat-
ment led to increased T cell numbers in the absence of proliferation 
(Extended Data Fig. 6l, m). Notably, CD8+PD1+ T cells from NASH 
mice showed reduced levels of FOXO1, which indicates an enhanced 
tissue-residency phenotype30, potentially combined with boosted 
effector function, as indicated by higher calcium levels in CD8+PD1+ 
T cells (Extended Data Fig. 6n, o). Single-cell RNA-seq analysis also 
showed that CD8+PD1+ T cells from NASH mice had a tissue residency 
signature (Extended Data Fig. 6b). Thus, upon anti-PD1 immuno-
therapy in NASH mice, CD8+PD1+ T cells accumulated to high numbers 
in the liver, revealing a resident-like T cell character with increased 
expression of CD44, CXCR6, EOMES and TOX and low levels of CD244 
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expression, but lacking expression of TCF1/TCF7, CD62L, TBET, and 
CD127 (Extended Data Fig. 6p–u). In summary, anti-PD1 immuno-
therapy increased the abundance of CD8+PD1+ T cells with a residency 
signature in the liver.
To investigate the mechanisms that drive the increased NASH–HCC 
transition in the preventive anti-PD1 treatment-setting, we treated 
NASH-affected mice with combinations of treatments. Both anti-CD8–
anti-PD1 and anti-TNF–anti-PD1 antibody treatments ameliorated liver 
damage, liver pathology and liver inflammation (Fig. 2g, Extended 
Data Fig. 7), and decreased the incidence of liver cancer compared 
to anti-PD1 treatment alone (Fig. 2i). By contrast, anti-CD4–anti-PD1 
treatment did not reduce the incidence of liver cancer, the NAFLD 
activity score (NAS), or the number of TNF-expressing hepatic CD8+ 
or CD8+PD1+CXCR6+ T cells (Fig. 2g–i, Extended Data Fig. 7). However, 
both the number of tumours per liver and tumour size were reduced, 
suggesting that depletion of CD4+ T cells or regulatory T cells might 
contribute to tumour control (Extended Data Fig. 8a, b). The incidence 
of tumours was directly correlated with anti-PD1 treatment, alanine 
aminotransferase (ALT), NAS, number of hepatic CD8+PD1+ T cells, and 
TNF expression (Extended Data Fig. 8c–e). These data suggested that 
CD8+PD1+ T cells lacked immune-surveillance and had tissue-damaging 
functions27, which were increased by anti-PD1 treatment, possibly con-
tributing to the unfavourable effects of anti-PD1 treatment on HCC 
development in NASH.
Augmented CD8+PD1+ T cells in human-NASH
We next investigated CD8+ T cells from healthy or NAFLD/NASH-affected 
livers. In two independent cohorts of patients with NASH, we found 
enrichment of hepatic CD8+PD1+ T cells with a residency phenotype (by 
flow cytometry and mass cytometry) (Fig. 3a, b, Extended Data Fig. 9a–j, 
Supplementary Tables 1,2). The number of hepatic CD8+PD1+ T cells 
directly correlated with body-mass index and liver damage (Extended 
Data Fig. 9b). To investigate similarities between mouse and human 
T cells from livers with NASH, we analysed liver CD8+PD1+ T cells from 
patients with NAFLD or NASH by scRNA-seq. This identified a gene 
expression signature that was also found in liver T cells from NASH 
mice (for example, PDCD1, GZMB, TOX, CXCR6, RGS1, SELL) (Fig. 3c, d, 
Extended Data Fig. 9k, l). Differentially expressed genes were directly 
correlated between patient- and mouse-derived hepatic CD8+PD1+ 
T cells (Fig. 3d). Velocity-blot analyses identified CD8+ T cells expressing 
TCF7, SELL and IL7R as root cells, and CD8+PD1+ T cells as their endpoints 
(Fig. 3e, f), indicating a local developmental trajectory of CD8+ T cells 
into CD8+PD1+ T cells. The amount of gene expression and velocity 
magnitude, which indicate transcriptional activity, were increased in 
CD8+PD1+ T cells from mice and humans with NASH (Fig. 3e). The expres-
sion of specific marker genes (for example, IL7R, SELL, TCF7, CCL5, 
CCL3, PDCD1, CXCR6, RGS1 and KLF2) along the latent time in patients 
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Fig. 1 | NASH progression is associated with increased, activated CD8+PD1+ 
T cells. a, CD8 and PD1 staining (right) and quantification (left) of T cells from 
mice fed normal diet (ND), CD-HFD or western-style diet with trans fat 
(WD-HTF) by immunohistochemistry. b, Immunofluorescence-based 
detection of PD1 (green), CD8 (red) and CD4 (yellow) cells. Scale bar, 100 μm.  
c, GSEA of hepatic CD8+PD1+ T cells sorted from TCRβ+ cells by mass 
spectrometry. FDR, false discovery rate; NES, normalized enrichment score.  
d–f, t-distributed stochastic neighbour embedding (tSNE) of TCRβ+ cells (d), 
differential gene expression by scRNA-seq (e) and scheme for experiment (f): 
mice were fed CD-HFD for 13 months and then treated with anti-PD1 for 8 weeks 
before measurement of tumour incidence. Mem, memory CD4 T cells.  
g, Livers from treated and untreated mice after CD-HFD. Arrowheads, tumours 
or lesions. Scale bar, 10 mm. h, Quantification of CD8+ cell in liver by 
immunohistochemistry. Details of sample sizes, biological replicates and 
statistical tests are given in Methods and Source Data. a, h, P values shown 
above brackets.
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(Fig. 3g), and correlated with the expression patterns seen in CD8+ 
T cells from NASH mice (Fig. 3h). Thus, scRNA-seq analysis demon-
strated a resident-like liver CD8+PD1+ T cell population in patients with 
NAFLD or NASH that shared gene expression patterns with hepatic 
CD8+PD1+ T cells from NASH mice.
Different stages of NASH severity are considered to herald the devel-
opment of liver cancer31. Indeed, different fibrosis stages (F0–F4) in 
patients with NASH correlated directly with the expression of PDCD1, 
CCL2, IP10 and TNF, and the degree of fibrosis correlated with the num-
bers of CD4+, PD1+, and CD8+ T cells (Extended Data Fig. 10a–d, Supple-
mentary Table 3). Moreover, PD1+ cells were absent from healthy livers 
but present in the livers of patients with NASH or NASH–HCC, but the 
number of these cells did not differ with the underlying fibrosis level 
(Extended Data Fig. 10e, Supplementary Tables 4–6). Species-specific 
effects, such as the absence in mice of cirrhosis or burnt-out NASH 
(a condition found in some patients with NASH–HCC32), and their pos-
sible influence on immunotherapy may make it difficult to translate 
findings from preclinical models of NASH to human NASH. However, 
in tumour tissue from patients with NASH-induced HCC—treated with 
anti-PD1 therapy—we found increased numbers of intra-tumoral PD1+ 
cells compared to patients with HCC and viral hepatitis (Extended 
Data Fig. 10f). Thus, we found a shared gene-expression profile and 
increased abundance of unconventionally activated hepatic CD8+PD1+ 
T cells in human NASH tissue.
Lack of immunotherapy response in human NASH–HCC
To explore the concept of disrupted immune surveillance in NASH 
after anti-PD1 or anti-PDL1 treatment, we conducted a meta-analysis 
of three large randomized controlled phase III trials of immunothera-
pies in patients with advanced HCC (CheckMate-45911, IMbrave1505 
and KEYNOTE-24010). Although immunotherapy improved survival 
in the overall population (hazard ratio (HR) 0.77; 95% confidence 
interval (CI) 0.63–0.94), survival was superior to the control arm in 
patients with HBV-related HCC (n = 574; P = 0.0008) and HCV-related 
HCC (n = 345; P = 0.04), but not in patients with non-viral HCC (n = 737; 
P = 0.39) (Fig. 4a, Extended Data Fig. 10g, Supplementary Table 7). 
Patients with viral aetiology (HBV or HCV infection) of liver damage 
and HCC showed a benefit from checkpoint inhibition (HR 0.64; 95% 












































































































































































































































































































































































































































































Fig. 2 | Resident-like CD8+PD1+ T cells drive hepatocarcinogenesis in a 
TNF-dependent manner upon anti-PD1 treatment in NASH.  
a, b, RNA-velocity analyses of scRNA-seq data showing expression (a) and 
correlation of expression (b) along the latent time of selected genes in CD8+ 
T cells from mice with NASH. Latent time (pseudo-time by RNA velocity): dark 
colour, start of RNA velocity; yellow, end point of latent time. Kendall’s τ, gene 
expression along latent time. c, Principal component analysis (PCA) plot of 
hepatic CD8+ and CD8+PD1+ T cells sorted by mass spectrometry from TCRβ+ 
cells from mice fed for 12 months with ND, CD-HFD or CD-HFD and treated for 
8 weeks with anti-PD1 antibodies. d, e, UMAP representations showing 
FlowSOM-guided clustering (d, left), heat map showing median marker 
expression (d, right), and quantification of hepatic CD8+ T cells (e) from mice 
fed for 12 months with ND or CD-HFD and treated for 8 weeks with IgG or 
anti-PD1 antibodies. f, Quantification of CellCNN-analysed flow cytometry data 
for hepatic CD8+ T cells from mice fed for 12 months with CD-HFD and treated 
for 8 weeks with IgG or anti-PD1 antibodies. g, h, NAS evaluation (g) and 
quantification of hepatic CD8+PD1+CXCR6+ T cells (h) from mice fed with ND for 
12 months or fed with CD-HFD for 12 months and treated for 8 weeks with 
anti-PD1, anti-PD1 + anti-CD8, anti-TNF, anti-PD1 + anti-TNF, anti-CD4, or 
anti-PD1 + anti-CD4 antibodies. Kendall’s τ, gene expression along latent time.  
i, Quantification of tumour incidence in mice as in g, h. Details of sample sizes, 
biological replicates and statistical tests are given in Methods and Source Data. 
e–i, P values shown above brackets.
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did not (HR 0.92; 95% CI 0.77–1.11; P of interaction = 0.03 (Fig. 4a)). 
Subgroup analysis of first-line treatment compared to a control arm 
treated with sorafenib (n = 1,243) confirmed that immunotherapy was 
superior in patients with HBV-related (n = 473; P = 0.03) or HCV-related 
HCC (n = 281; P = 0.03), but not in patients with non-viral HCC (n = 489; 
P = 0.62; Extended Data Fig. 10h–j). We acknowledge that these results 
were derived from a meta-analysis of trials that included different lines 
of treatment and patients with heterogeneous liver damage, and did 
not differentiate between alcoholic liver disease and NAFLD or NASH. 
Nevertheless, the results of this meta-analysis supported the notion 
that stratification of patients according to the aetiology of their liver 
damage and ensuing HCC identified patients who responded well to 
therapy.
To specifically characterize the effect of anti-PD(L)1 immunotherapy 
with respect to underlying liver disease, we investigated a cohort of 
130 patients with HCC (patients with NAFLD n = 13; patients with other 
aetiologies n = 117) (Supplementary Table 8). NAFLD was associated with 
shortened median overall survival after immunotherapy (5.4 months 
(95% CI 1.8–9.0 months) versus 11.0 months (95% CI 7.5–14.5 months); 
P = 0.023), even though patients with NAFLD had less frequent macro-
vascular tumour invasion (23% versus 49%), and immunotherapy was 























































































































































































































































































































Root cells End points Latent time
Fig. 3 | Hepatic resident-like CD8+PD1+ T cells are increased in livers of 
patients with NAFLD patients. a, b, UMAP representation showing the 
FlowSOM-guided clustering of CD45+ cells (a) and flow cytometry plots (b, left) 
and quantification (b, right) of CD8+PD1+CD103+ cells derived from hepatic 
biopsies of healthy individuals or patients with NAFLD or NASH 
(Supplementary Table 2). Populations in b: violet, CD8+; red, CD8+PD1+CD103+. 
Treg cells, regulatory T cells. c, UMAP representations and analyses of 
differential gene expression by scRNA-seq of CD3+ cells from control 
individuals or patients with NAFLD or NASH. MAITs, mucosal-associated 
invariant T cells. d, Correlation of significant differentially expressed genes in 
liver-derived CD8+PD1+ T cells compared to CD8+PD1− T cells from mice fed with 
CD-HFD for 12 months and patients with NAFLD/NASH. Shading shows 95% CI. 
e–h, Expression (e) and transcriptional activity (f) of velocity analyses of 
scRNA-seq data, and gene expression (g) and correlation (h) of expression 
along the latent-time of selected genes along the latent-time of liver-derived 
CD8+ T cells from patients with NAFLD or NASH in comparison to control or 
NASH mouse liver-derived CD8+ T cells. Root cells: yellow, root cells; blue, cells 
furthest from the root by RNA velocity. End points: yellow, end-point cells; 
blue, cells furthest from defined end-point cells by RNA velocity. Latent time 
(pseudo-time by RNA velocity): dark colour, start of RNA velocity; yellow, end 
point of latent time. RNA velocity flow (top): blue cluster, start point; orange 
cluster, intermediate; green cluster, end point. Arrow indicates cell trajectory. 
Details of sample sizes, biological replicates and statistical tests are given in 
Methods and Source Data. b, e, P values shown above brackets.
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Fig. 4b). After correction for potentially confounding factors that are 
relevant for prognosis, including severity of liver damage, macrovascu-
lar tumour invasion, extrahepatic metastases, performance status, and 
alpha-fetoprotein (AFP), NAFLD remained independently associated 
with shortened survival of patients with HCC after anti-PD1-treatment 
(HR 2.6; 95% CI 1.2–5.6; P = 0.017, Supplementary Table 9). This finding 
was validated in a further cohort of 118 patients with HCC who were 
treated with PD(L)1-targeted immunotherapy (patients with NAFLD 
n = 11; patients with other aetiologies n = 107) (Supplementary Table 10). 
NAFLD was again associated with reduced survival of patients with 
HCC (median overall survival 8.8 months, 95% CI 3.6–12.4 months) 
compared to other aetiologies of liver damage (median overall sur-
vival 17.7 months, 95% CI 8.8–26.5 months; P = 0.034) (Fig. 4c). Given 
the relatively small number of patients with NAFLD in both cohorts, 
these data need prospective validation. However, collectively these 
results indicate that patients with underlying NASH did not benefit 
from checkpoint-inhibition therapy.
Liver cancer develops primarily on the basis of chronic inflamma-
tion. The latter can be activated by immunotherapy to induce tumour 
regression in a subset of patients with liver cancer. However, the iden-
tification of patients who will respond to immunotherapy for HCC 
remains difficult. Our data identify a non-viral aetiology of liver dam-
age and cancer (that is, NASH) as a predictor of unfavourable outcome 
in patients treated with immune-checkpoint inhibitors. The better 
response to immunotherapy in patients with virus-induced HCC than 
in patients with non-viral HCC might be due to the amount or quality 
of viral antigens or to a different liver micro-environment, possibly one 
that does not impair immune surveillance. These results might also have 
implications for patients with obesity and NALFD or NASH who have 
cancer at other organ sites (for example, melanoma, colon carcinoma, 
or breast cancer) and are at risk for liver damage and the development 
of liver cancer in response to systemically applied immunotherapy. 
Overall, our results provide comprehensive mechanistic insight and 
a rational basis for the stratification of patients with HCC according 
to their aetiology of liver damage and cancer for the design of future 
trials of personalized cancer therapy.
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Methods
Mice, diets, and treatments
Standard mouse diet feeding (ad libitum water and food access) and 
treatment regimens were as described previously17. Male mice were 
housed at the German Cancer Research Center (DKFZ) (constant tem-
perature of 20–24 °C and 45–65% humidity with a 12-h light–dark cycle). 
Mice were maintained under specific pathogen-free conditions and 
experiments were performed in accordance with German law and the 
governmental bodies, and with approval from the Regierungspräsidium 
Karlsruhe (G11/16, G129/16, G7/17). Tissues from inducible knock-in 
mice expressing the human unconventional prefoldin RPB5 interactor 
were received from N. Djouder17,33. The plasmids for hydrodynamic 
tail-vein delivery have been described previously34–37. For interven-
tional studies, male mice fed a CD-HFD were treated with bi-weekly for 
8 weeks by intravenous injection of 25 μg CD8-depleting antibody (Biox-
cell, 2.43), 50 μg NK1.1-depleting antibody (Bioxcell, PK136), 300 μg 
anti-PDL1 (Bioxcell, 10F.9G2), 200 μg anti-TNF (Bioxcell, XT3.11), 100 μg 
anti-CD4 (Bioxcell, GK1.5), or 150 μg anti-PD1 (Bioxcell, RMP1-14). 
PD1−/− mice were kindly provided by G. Tiegs and K. Neumann. Mice 
for Extended Data Fig. 3g were treated with anti-PD1 antibody (Bioxcell, 
RMP1-14) or isotype control (Bioxcell, 2A3) at an initial dose of 500 μg 
intraperitoneally (i.p.) followed by doses of 200 μg i.p. bi-weekly for 
8 weeks. Mice for Extended Data Fig. 3h were treated i.p. with anti-PD1 
(200 μg, Bioxcell, RMP1-14) or IgG (200 μg, Bioxcell, LTF-2). The treat-
ment regimen for Extended Data Fig. 3i was as described elserwhere38.
Intraperitoneal glucose tolerance test and measurement of serum 
parameters were as described previously17.
Magnetic resonance Imaging
MRI was done in the small animal imaging core facility in DKFZ using 
a Bruker BioSpec 9.4 Tesla (Ettlingen). Mice were anaesthetized with 
3.5% sevoflurane, and imaged with T2-weighted imaging using a T2_
TurboRARE sequence: TE = 22 ms, TR = 2,200 ms, field of view (FOV) 
35 × 35 mm, slice thickness 1 mm, averages = 6, scan time 3 min 18 s, 
echo spacing 11 ms, rare factor 8, slices 20, image size 192 × 192 pixels, 
resolution 0.182 × 0.182 mm.
Multiplex ELISA
Liver homogenates were prepared as for western blotting17 and 
cytokines or chemokines were analysed on a customized ELISA accord-
ing to the manufacturer’s manual (Meso Scale Discovery, U-PLEX Bio-
marker group 1, K15069L-1).
Flow cytometry and FACS
Isolation and staining of lymphocytes. After perfusion and mechani-
cal dissection, livers were incubated for up to 35 min at 37 °C with col-
lagen IV (60 U final concentration (f.c.)) and DNase I (25 μg/ml f.c.), fil-
tered at 100 μm, and washed with RPMI1640 (11875093, Thermo Fisher). 
Next, samples underwent a two-step Percoll gradient (25%/50% Percoll/
HBSS) and centrifugation for 15 min at 1,800g and 4 °C. Enriched leu-
kocytes were then collected, washed, and counted. For re-stimulation, 
cells were incubated for 2 h at 37 °C under 5% CO2 with 1:500 Biolegend´s 
Cell Activation Cocktail (with brefeldin A) (423304) and 1:1,000 Monen-
sin Solution (420701). Live/dead discrimination was done using DAPI or 
ZombieDyeNIR according to the manufacturer’s instructions with sub-
sequent staining of titrated antibodies (Supplementary Tables 12–14). 
Samples for flow cytometric-activated cell sorting (FACS) were sorted 
and samples for flow cytometry were fixed using eBioscience IC fixa-
tion (00-8222-49) or FOXP3 Fix/Perm kit (00-5523-00) according to 
the manufacturer’s instructions. Intracellular staining was performed 
in eBioscience Perm buffer (00-8333-56). Cells were analysed using 
BD FACSFortessa or BD FACSSymphony and data were analysed using 
FlowJo (v10.6.2). For sorting, FACS Aria II and FACSAria FUSION were 
used in collaboration with the DKFZ FACS core facility.
For UMAP and FlowSOM plots, BD FACSymphony data (mouse and 
human) were exported from FlowJo (v10). Analyses were performed 
as described elsewhere39.
Single-cell RNA-seq and metacell analysis (mouse)
Single-cell capturing for scRNA-seq and library preparation were done 
as described previously40. Libraries (pooled at equimolar concentra-
tion) were sequenced on an Illumina NextSeq 500 at a median sequenc-
ing depth of ~40,000 reads per cell. Sequences were mapped to the 
mouse genome (mm10), using HISAT (version 0.1.6); reads with multiple 
mapping positions were excluded. Reads were associated with genes 
if they were mapped to an exon, using the Ensembl gene annotation 
database (Ensembl release 90). Exons of different genes that shared 
a genomic position on the same strand were considered to represent 
a single gene with a concatenated gene symbol. The level of spurious 
unique molecular identifiers (UMIs) in the data was estimated by using 
statistics on empty MARS-seq wells and excluded rare cases with esti-
mated noise >5% (median estimated noise overall for experiments was 
2%). Specific mitochondrial genes, immunoglobulin genes, genes linked 
with poorly supported transcriptional models (annotated with the 
prefix “Rp-”), and cells with fewer than 400 UMIs were removed. Gene 
features were selected using Tvm = 0.3 and a minimum total UMI count 
>50. We carried out hierarchical clustering of the correlation matrix 
between those genes (filtering genes with low coverage and computing 
correlation using a down-sampled UMI matrix) and selected the gene 
clusters that contained anchor genes. We used K = 50, 750 bootstrap 
iterations, and otherwise standard parameters. Subsets of T cells were 
obtained by hierarchical clustering of the confusion matrix and super-
vised analysis of enriched genes in homogeneous groups of metacells41.
Velocity and correlation analyses of scRNA-seq data
Velocyto (0.6) was used to estimate the spliced and unspliced counts 
from the pre-aligned bam files42. RNA velocity, latent time, root, and 
terminal states were calculated using the dynamical velocity model 
from scvelo (0.2.2)43. Kendall’s rank correlation coefficient (τ) was used 
to correlate the expression patterns of biologically significant genes 
with latent time.
Preparation for mass spectrometry, data acquisition, and data 
analysis
After FACS purification, cells were resuspended in 50% (vol/vol) 
2,2,2-trifluoroethanol in PBS pH 7.4 buffer and lysed by repeated sonica-
tion and freeze–thaw cycles. Proteins were denatured at 60 °C for 2 h, 
reduced using dithiothreitol at a final concentration of 5 mM (30 min 
at 60 °C), cooled to room temperature, alkylated using iodoacetamide 
at 25 mM (30 min at room temperature in the dark), and diluted 1:5 
using 100 mM ammonium bicarbonate, pH 8.0. Proteins were digested 
overnight by trypsin (1:100 ratio, 37 °C), desalted using C18-based 
stage-tips, dried under vacuum, resuspended in 20 μl HPLC-grade 
water with 0.1% formic acid, and measured using A380.
We used 0.5 μg of peptides for proteomic analysis on a C18 col-
umn using a nano liquid chromatography system (EASY-nLC 1200, 
Thermo Fisher Scientific). Peptides were eluted using a gradient of 
5–30% buffer B (80% acetonitrile and 0.1% formic acid) at a flow rate 
of 300 nl/min at a column temperature of 55 °C. Data were acquired 
by data-dependent Top15 acquisition using a high-resolution orbitrap 
tandem mass spectrometer (QExactive HFX, Thermo Scientific). All MS1 
scans were acquired at 60,000 resolution with AGC target of 3 × 106, 
and MS2 scans were acquired at 15,000 resolution with AGC target of 
1 × 105 and maximum injection time of 28 ms. Analyses were performed 
using MaxQuant (1.6.7.0), mouse UniProt Isoform fasta (Version: 2019-
02-21, number of sequences 25,233) as a source for protein sequences. 
One per cent FDR was used for controlling at the peptide and protein 
levels, with a minimum of two peptides needed for consideration of 
analysis. GSEA was performed using ClusterProfiler (3.18)44 and gene 
sets obtained from WikiPathway (https://www.wikipathways.org/) and 
MSigDB (https://broadinstitute.org/msigdb)45–47.
Histology, immunohistochemistry, scanning, and automated 
analysis
Histology, immunohistochemistry, scanning, and automated analysis 
have been described previously17. Antibodies used in this manuscript 
are described in Supplementary Table 12. For immunofluorescence 
staining, established antibodies were used, coupled with the AKOYA 
Biosciences Opal fluorophore kit (Opal 520 FP1487001KT, Opal 540 
FP1494001KT, Opal 620 FP1495001KT). For mRNA in situ hybridization, 
freshly non-baked 5 μm formalin-fixed paraffin-embedded sections 
were cut and stained according to the manufacturer’s (ACD biotech) 
protocol for manual assay RNAscope, using probes PDL1 (420501), TNF 
(311081) and CXCR6 (871991).
Isolation of RNA and library preparation for bulk RNA 
sequencing
RNA isolation17 and library preparation for bulk 3′-sequencing of 
poly(A)-RNA was as described previously48. Gencode gene annotations 
version M18 and the mouse reference genome major release GRCm38 
were derived from https://www.gencodegenes.org/. Dropseq tools 
v1.1249 were used for mapping the raw sequencing data to the reference 
genome. The resulting UMI-filtered count matrix was imported into 
R v3.4.4. Before differential expression analysis with Limma v3.40.650 
sample-specific weights were estimated and used as coefficients along-
side the experimental groups as a covariate during model fitting with 
Voom. t-test was used for determining differentially (P < 0.05) regulated 
genes between all possible experimental groups. GSEA was conducted 
with the pre-ranked GSEA method46 within the MSigDB Reactome, 
KEGG, and Hallmark databases (https://broadinstitute.org/msigdb). 
Raw sequencing data are available at European Nucleotide Archive 
(https://www.ebi.ac.uk/ena/browser/home) under the accession num-
ber PRJEB36747.
Stimulation of CD8 T cells
Stimulation of CD8 T cells was as described elsewhere27.
Flow cytometry of human biopsies
Analysis of patient material (Supplementary Table 1) was performed 
on liver tissue (needle biopsies or resected tissue, BIOFACS Study 
KEK 2019-00114), which were obtained from the patient collection 
nAC-2019-3627 (CRB03) from the biological resource centre of CHU 
Grenoble-Alpes (nBRIF BB-0033-00069). Tissue samples were minced 
using scalpels, incubated (with 1 mg/ml collagenase IV (Sigma Aldrich), 
0.25 μg/ml DNase (Sigma Aldrich), 10% FCS (Thermo Fisher Scien-
tific), RPMI 1640 (Seraglob)) for 30 min at 37 °C, stopping enzymatic 
reactions with 2 mM EDTA (StemCell Technologies, Inc.) in PBS. After 
filtering through a 100-μm cell strainer, cells were resuspended in 
FACS buffer (PBS, EDTA 2 mM, FCS 0.5%) with Human TruStain FcX (Fc 
Receptor Blocking Solution) (Biolegend), incubated for 15 min at 4 °C 
and stained with antibodies (Supplementary Table 13).
Flow cytometry of human samples (Extended Data Fig. 9f) was 
approved by the local ethical committee (AC-2014-2094 n 03).
High-throughput RNA-seq of human samples
As previously reported, RNA-seq analysis was performed using the 
data from 206 snap-frozen biopsy samples from 206 patients diag-
nosed with NAFLD in France, Germany, Italy, and the UK and enrolled 
in the European NAFLD Registry (GEO accession GSE135251)51,52. Sam-
ples were scored for NAS by two pathologists53. Alternate diagnoses 
were excluded, including excessive alcohol intake (30 g per day for 
males, 20 g for females), viral hepatitis, autoimmune liver diseases, 
and steatogenic medication use. Patient samples were grouped: NAFL 
(n = 51) and NASH with fibrosis stages of F0/1 (n = 34), F2 (n = 53), 
F3 (n = 54) and F4 (n = 14). Collection and use of data of the European 
NAFLD Registry were approved by the relevant local and/or national 
Ethical Review Committee51. A correction for sex, batch, and centre 
effects was implemented. Pathway enrichment and visualization were 
as described elsewhere52,54,55.
Immunohistochemistry of NAFLD/NASH cohort
Sixty-five human FFPE biopsies from patients with NAFLD were included 
(Supplementary Table 3). Sequential slides were immunostained with 
antibodies against human CD8 (Roche, SP57, ready-to-use), PD1 (Roche; 
NAT105, ready-to-use), and CD4 (Abcam, ab133616, 1:500). All stain-
ing was performed on the VENTANA BenchMark autostainer at 37 °C. 
Immunopositive cells were quantified at 400× magnification in the 
portal tract and the adherent parenchyma.
Isolation of cells for scRNA-seq data analysis (human)
Analyses used liver samples from patients undergoing bariatric sur-
gery at the Department of Surgery at Heidelberg University Hospital 
(S-629/2013). Samples were preserved by FFPE for pathological evalu-
ation and single cells were generated by mincing, using the Miltenyi 
tumour dissociation kit (130-095-929) per the manufacturer’s instruc-
tions, filtering through a 70-μm cell strainer and washing. ACK lysis 
using the respective buffer (Thermo Fischer Scientific A1049201) was 
performed, and samples were stored in FBS with 20% DMSO until fur-
ther processing (scRNA-seq analysis and mass cytometry).
Cells were thawed in a 37 °C water bath, washed with PBS + 0.05 mM 
EDTA (10 min, 300g at 4 °C), Fc receptor-block (10 min at 4 °C), stained 
with CD45-PE (3 μl, Hl30, 12-0459-42) and Live/Dead discrimination 
(1:1,000, Thermofischer, L34973), washed and sorted on a FACSAria 
FUSION in collaboration with the DKFZ FACS. Library generation was 
performed according to the manufacturer’s protocol (Chromium Next 
EM Single Cell 3′GEM, 10000128), and sequencing was performed on 
an Illumina NovaSeq 6000. De-multiplexing and barcode processing 
were performed using the Cell Ranger Software Suite (Version 4.0.0) 
and reads were aligned to human GRCh3856. A gene–barcode matrix 
containing cell barcodes and gene expression counts was generated by 
counting the single-cell 3′ UMIs, which were imported into R (v4.0.2), 
where quality control and normalization were executed using Seurat 
v357. Cells with more than 10% mitochondrial genes, fewer than 200 
genes per cell, or more than 6,000 genes per cell were excluded. Matri-
ces from 10 samples were integrated with Seurat v3 to remove batch 
effects across samples. PCA analysis of filtered gene–barcode matrices 
of all CD3+ cells, visualized by UMAP (top 50 principal components), 
and identification of major cell types using the highly variable features 
and indicative markers were performed. Pairwise comparisons of CD4+ 
T cells versus CD4+PD1+ T cells and CD8+ T cells versus CD8+PD1+ T cells 
were performed using the results of differential expression analysis by 
DESeq2 (v1.28.1)58, setting CD4+/CD8+ T cells as controls. Volcano plots 
were then generated using EnhancedVolcano (v1.6.0)59 to visualize the 
results of differential expression analysis.
Mass cytometry data analysis (human)
Antibody conjugates for mass cytometry were purchased from Flui-
digm, generated in-house using antibody labelling kits (Fluidigm 
X8, MCP9), or as described before60,61. Antibody cocktails for mass 
cytometry were cryopreserved as described before62. Isolation of cells is 
described in ‘Isolation of cells for scRNA-seq data analysis (human)’. Cells 
were thawed, transferred into RPMI + benzonase (14 ml RPMI + 0.5 μl 
benzonase), and centrifuged for 5 min at 500g. The cell pellet was 
resuspended in 1 ml CSM-B (CSM (PBS 0.5% BSA 0.02% sodium azide) 
+1 μl benzonase), filtered through a 30-μm cell strainer, adjusted to 
3 ml, counted, resuspended in 35 μl CSM-B and incubated for 45 min 
at 4 °C, and 100 μl CSM-B was added. Cells were pooled and stained 
with a surface antibody cocktail (Supplementary Table 15) for 30 min 
at 4 °C. Dead cell discrimination was performed with mDOTA-103Rh 
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(5 min, room temperature). For intracellular staining, the FOXP3 intra-
cellular staining kit from Miltenyi Biotec was used per the manufactur-
er’s instructions, followed by staining for intracellular targets for 30 min 
at room temperature. Cells were washed, resuspended in 1 ml of iridium 
intercalator solution, and incubated for 25 min at room temperature. 
Cells were washed with CSM, PBS, and MilliQ water, adjusted to a final 
concentration of 7.5 × 105 cells/ml and supplemented with 4-element 
EQ beads. The sample was acquired on a Helios mass cytometer and 
raw data were EQ-Bead-normalized using Helios mass cytometer and 
Helios instrument software (version 6.7). Compensation was performed 
in CATALYST (v1.86)63 and FlowCore (1.50.0). De-barcoding and gat-
ing of single, live CD45+ cells were performed using FlowJo (v10.6.2). 
Then, data from CD45+ cells were imported into Cytosplore 2.3.1 and 
transformed using the arcsinh(5) function. Major immune cell lineages 
were identified at the first level of a two-level hierarchical stochastic 
neighbour embedding (HSNE) analysis with default perplexity and 
iteration settings. HSNE with the same parameters was run on CD3+ 
cells to identify T cell phenotypes. Gaussian mean shift clustering was 
performed in Cytosplore and a heat map of arcsinh(5)-transformed 
expression values of all antibody targets was generated. Cell type iden-
tification was based on the transformed expression values and clusters 
showing high similarity were merged manually.
Histological and immunohistochemical analysis of NASH–HCC 
cohort
Four healthy samples, 16 samples from patients with NASH cases, and 
non-tumoral tissue adjacent to HCC tumours from patients of the follow-
ing aetiologies were selected: NASH (n = 26), viral hepatitis (n = 19 HCV, 
n = 3 HBV), alcohol (n = 5), and other (n = 2). All samples were obtained 
from International Genomic HCC Consortium with IRB approval. After 
heat-induced antigen retrieval (10 mM sodium citrate buffer (pH 6.0) or 
Universal HIER antigen retrieval reagent (ab208572) for 15 min (3 × 5 min), 
the reaction was quenched using 3% hydrogen peroxide. Samples were 
washed with PBS and incubated with anti-CD8 (Cell Signaling, Danvers, 
MA) or anti-PD1 (NAT105, ab52587). DAB (3,3′-diaminobenzidine) was 
used as a detection system (EnVision+ System-HRP, Dako). PD1-positive 
cases were defined by considering median positivity by immunohis-
tochemistry64 and using a cutoff of ≥1% of PD1-positive lymphocytes 
among all lymphocytes present on each slide. Analysis of human samples 
from the Department of Pathology and Molecular Pathology, University 
Hospital Zurich (Extended Data Fig. 10), was approved by the local ethics 
committee (Kantonale Ethikkommission Zürich, KEK-ZH-Nr. 2013-0382 
and BASEC-Nr. PB_2018-00252).
Search strategy, selection criteria, and meta-analysis of phase III 
clinical trials
The literature search was done through MEDLINE on PubMed, Cochrane 
Library, Web of Science, and clinicaltrials.gov, using the following 
searches: ‘checkpoint inhibitors’, ‘HCC’, ‘phase III’, between January 2010 
and January 2020, and complemented by manual searches of confer-
ence abstracts and presentations. Single-centre, non-controlled trials, 
studies with insufficient data to extract HRs or 95% confidence intervals, 
and trials including disease entities other than HCC were excluded. 
As conference abstracts were not excluded, quality assessment of the 
included studies was not performed. Three studies5,10,11 fulfilled the 
criteria and were included in the quantitative synthesis (Extended Data 
Fig. 10). The primary outcome of the meta-analysis was overall survival, 
defined as the time from randomization to death. HRs and CIs related 
to overall survival were extracted from the papers or conference pres-
entations5,10,11. Pooled HRs were calculated using the random-effects 
model and we used the DerSimonian–Laird method to estimate τ2, 
and the generic inverse variance was used for calculating weights 65. 
To evaluate heterogeneity among studies, Cochran’s Q test and I2  
index were used. P < 0.10 in the Q-test was considered to indicate sub-
stantial heterogeneity. I2 was interpreted as suggested in the literature: 
0% to 40% might not represent significant heterogeneity; 30% to 60% 
may represent moderate heterogeneity; 50% to 90% may represent 
substantial heterogeneity; 75% to 100% represents considerable 
heterogeneity. All statistical pooled analyses were performed using 
RevMan 5.3 software.
A cohort of patients with HCC treated with PD(L)1-targeted 
immunotherapy
The retrospective analysis was approved by local Ethics Committees. 
Data from this cohort were published previously66. Patients with 
liver cirrhosis and advanced-stage HCC treated with PD(L)1-targeted 
immune checkpoint blockers from 12 centres in Austria, Germany, Italy, 
and Switzerland were included. The χ2 test or Fisher’s exact test were 
used to compare nominal data. Overall survival was defined as the time 
from the start of checkpoint inhibitor treatment until death. Patients 
who were still alive were censored at the date of the last contact. Survival 
curves were calculated by the Kaplan–Meier method and compared by 
using the log-rank test. Multivariable analysis was performed by a Cox 
regression model. Statistical analyses were performed using IBM SPSS 
Statistics version 25 (SPSS Inc., Chicago, IL).
A validation cohort of patients with HCC treated with 
PD1-targeted immune checkpoint blockers
A multi-institutional dataset that included 427 patients with HCC 
treated with immune checkpoint inhibitors between 2017 and 2019 in 
11 tertiary-care referral centres specialized in the treatment of HCC was 
analysed. Clinical outcomes of this patient cohort have been reported 
elsewhere67,68. Inclusion criteria were: 1) diagnosis of HCC made by 
histopathology or imaging criteria according to American Association 
for the Study of Liver Disease and European Association for the Study 
of the Liver guidelines; 2) systemic therapy with immune checkpoint 
inhibitors for HCC that was not amenable to curative or loco-regional 
therapy following local multidisciplinary tumour board review; 3) 
measurable disease according to RECIST v1.1 criteria at commence-
ment of treatment with immune checkpoint inhibitors. One hundred 
and eighteen patients with advanced-stage HCC were recruited with 
Child–Pugh A liver functional reserve, and documented radiologic or 
clinical diagnosis of cirrhosis. Ethical approval to conduct this study 
was granted by the Imperial College Tissue Bank (reference number 
R16008).
Statistical analyses
No statistical methods were used to predetermine sample size. The 
experiments were not randomized and the investigators were not 
blinded to allocation during experiments and outcome assessment. 
Data were collected in Microsoft Excel. Mouse data are presented as 
the mean ± s.e.m. Pilot experiments and previously published results 
were used to estimate the sample size, such that appropriate statistical 
tests could yield significant results. Statistical analysis was performed 
using GraphPad Prism software version 7.03 (GraphPad Software). 
Exact P values lower than P < 0.1 are reported and specific tests are 
indicated in the legends.
Sample sizes, biological replicates and statistical tests
Fig. 1a: PD1, n = 5 mice/group; CD8, ND n = 6 mice; CD-HFD n = 6 mice; 
WD-HTF n = 5 mice. Scale bar, 100 μm. Fig. 1b: n = 3 mice/group. Scale 
bar, 100 μm. Fig. 1c: ND n = 4 mice, CD-HFD n = 6 mice. Fig. 1d, e: n = 3 
mice/group. Fig. 1f: tumour incidence: CD-HFD, n = 19 tumours/lesions 
in 25 mice; CD-HFD + anti-PD1, n = 10 tumours/lesions in 10 mice. Fig. 1h: 
ND, n = 3 mice; CD-HFD, n = 13 mice; CD-HFD + anti-PD1, n = 8 mice; 
intra-tumoral staining: CD-HFD, n = 11 mice; CD-HFD + anti-PD1, n = 8 
mice. Data in Fig. 1a, h were analysed by two-tailed Student’s t-test. Data 
in Fig. 1f were analysed by two-sided Fisher’s exact test.
Fig. 2a, b: n = 3 mice/group. Fig. 2c: CD8+: ND, n = 6 mice; CD-HFD + IgG, 
n = 5 mice; CD-HFD + anti-PD1, n = 6 mice; CD8+PD1+: ND, n = 4 mice, CD-HFD 
+ IgG, n = 6 mice; CD-HFD + anti-PD1, n = 6 mice. Fig. 2d, e: ND, n = 4 mice; 
CD-HFD + IgG, n = 8 mice; CD-HFD + anti-PD1, n = 6 mice. Fig. 2f: CD-HFD 
+ IgG, n = 6 mice; CD-HFD + anti-PD1, n = 4 mice. Fig. 2g: ND, n = 30 mice; 
CD-HFD, n = 47 mice; CD-HFD + anti-PD1, n = 35 mice; CD-HFD + anti-PD1/
anti-CD8, n = 9 mice; CD-HFD + anti-TNF, n = 10 mice; CD-HFD + anti-PD1/
anti-TNF, n = 11 mice; CD-HFD + anti-CD4, n = 8 mice; CD-HFD + anti-PD1/
anti-CD4, n = 8 mice. Fig. 2h: CD8+PD1+CXCR6+: ND, n = 30 mice; CD-HFD, 
n = 47 mice; CD-HFD + anti-PD1, n = 35 mice; CD-HFD + anti-PD1/anti-CD8, 
n = 9 mice; CD-HFD + anti-TNF, n = 10 mice; CD-HFD + anti-PD1/anti-TNF, 
n = 11 mice; CD-HFD + anti-CD4, n = 8 mice; CD-HFD + anti-PD1/anti-CD4, 
n = 8 mice. Fig. 2j: tumour incidence: CD-HFD, n = 32 tumours/lesions in 
87 mice; CD-HFD + anti-CD8, n = 2 tumours/lesions in 31 mice; CD-HFD + 
anti-CD8/NK1.1, n = 0 tumours/lesions in 6 mice; CD-HFD + anti-PD1, n = 33 
tumours/lesions in 44 mice; CD-HFD + anti-PD1/anti-CD8, n = 2 tumours/
lesions in 9 mice; CD-HFD + anti-TNF, n = 3 tumours/lesions in 10 mice; 
CD-HFD + anti-PD1/anti-TNF, n = 3 tumours/lesions in 11 mice; CD-HFD + 
anti-CD4, n = 3 tumours/lesions in 9 mice; CD-HFD + anti-PD1/anti-CD4, 
n = 8 tumours/lesions in 9 mice. All data are shown as mean ± s.e.m. Data 
in Fig. 2e, g, h were analysed by one-way ANOVA and Fisher’s LSD test. 
Data in Fig. 2f were analysed by two-tailed Mann–Whitney test. Data in 
Fig. 2j were analysed by two-sided Fisher’s exact test.
Fig. 3a, b: control, n = 6 patients; NAFLD/NASH, n = 11 patients. Fig. 3c: 
control, n = 4 patients; NAFLD/NASH, n = 7 patients. Fig. 3d–h: mouse, 
n = 3; human, n = 3. All data are shown as mean ± s.e.m. Data in Fig. 3b, f 
were analysed by two-tailed Mann–Whitney test. Data in Fig. 3d were 
analysed by two-tailed Spearman’s correlation.
Fig. 4a: Hazard ratios are represented by squares, the size of the 
square represents the weight of the trial in the meta-analysis. Cochran’s 
Q-test and I2 were used to calculate heterogeneity. Fig. 4b: Kaplan–
Meier curve displays overall survival of patients with NAFLD versus 
those with any other aetiology; all 130 patients were included in these 
survival analyses (NAFLD n = 13; any other aetiology n = 117). Fig. 4c: 
Kaplan–Meier curve displays overall survival of patients with NAFLD 
versus those with any other aetiology (NAFLD n = 11; any other aetiol-
ogy n = 107). Data in Fig. 4b, c were analysed by Kaplan–Meier method 
and compared using log rank test.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The proteomics data described in this article are available at the PRIDE 
database, under the identifier PXD017236 or through the dataset web-
site (http://www.ebi.ac.uk/pride/archive/projects/PXD017236). The 
bulk RNA-seq data described in this article are available at the European 
Nucleotide Archive (ENA) under accession number PRJEB36747. The 
scRNA-seq data described in this article are available at GEO under 
accession GSE144635. The array of comparative genomic hybridiza-
tion data described in this article is available at GEO under accession 
GSE144875. The results here are in whole or part based upon data gener-
ated by the TCGA Research Network (https://www.cancer.gov/tcga). 
The human scRNA-seq data described in this article are available at 
GEO under accession GSE159977. Databases used in this manuscript are 
WikiPathways (https://www.wikipathways.org/) and MSigDB (https://
broadinstitute.org/msigdb). Source data are provided with this paper.
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Extended Data Fig. 1 | T cell activation and hepatic abundance correlate 
with NASH pathology. a–c, Time kinetics of haematoxylin and eosin (H&E) 
staining of liver tissue (a), ALT (b), and NAS (c) in mice fed ND, CD-HFD, or  
WD-HTF (n ≥ 5 mice per group). Scale bar, 100 μm. H&E 3 months: ND n = 5 mice; 
CD-HFD n = 5 mice; WD-HTF n = 3 mice; 6 months: ND n = 16 mice; CD-HFD n = 8 
mice; WD-HTF n = 8 mice; 12 months: ND n = 9 mice; CD-HFD n = 12 mice; WD-
HTF n = 6 mice; ALT 3 months: ND n = 15 mice; CD-HFD n = 46 mice; WD-HTF 
n = 23 mice; 6 months: ND n = 46 mice; CD-HFD n = 59 mice; WD-HTF n = 21 mice; 
12 months: ND n = 25 mice; CD-HFD n = 69 mice; WD-HTF n = 5 mice; NAS 3 
months: ND n = 5 mice; CD-HFD n = 5 mice; WD-HTF n = 3 mice; 6 months: ND 
n = 16 mice; CD-HFD n = 8 mice; WD-HTF n = 8 mice; 12 months: ND n = 9 mice; 
CD-HFD n = 12 mice; WD-HTF n = 6 mice. d, e, H&E staining (d) with NAS 
evaluation by H&E (e, left) and ALT (e, right) of mice fed with ND, HFD or CD-
HFD for 3 months. NAS: ND n = 7 mice; CD-HFD n = 7 mice; HFD n = 5 mice; ALT: 
ND n = 8 mice; CD-HFD n = 8 mice; HFD n = 7 mice. Scale bar, 50 μm.  
f, g, Representative flow cytometry plots (f) and PD1 expression (g) of hepatic 
T cells from mice fed for 3 months with ND, HFD or CD-HFD (n = 4 mice per 
group). h, Heat map showing the median marker expression of the defined 
CD45+ subsets displayed in i by flow cytometry of cells from mice fed for 
12 months with ND or CD-HFD (ND n = 4 mice; CD-HFD n = 8 mice). i, UMAP 
representation of FlowSOM-guided clustering and quantification of hepatic 
immune cell composition of mice fed for 12 months with ND or CD-HFD (ND 
n = 4 mice; CD-HFD n = 8 mice). j, k, Abundance ( j), flow cytometry plots (k, left) 
and PD1 expression (k, right) of hepatic CD8+ T cells from mice fed for 6 or 
12 months with ND or CD-HFD (abundance of CD8 6 months: ND n = 17 mice;  
CD-HFD n = 10 mice; WD-HTF n = 7 mice; 12 months: ND n = 11 mice; CD-HFD n = 6 
mice; WD-HTF n = 5 mice; PD1 expression in CD8+ T cells 6 months: ND n = 15 
mice; CD-HFD n = 14 mice; WD-HTF n = 7 mice; 12 months: ND n = 10 mice;  
CD-HFD n = 6 mice; WD-HTF n = 5 mice). l, m, Abundance (l), flow cytometry 
plots (m, left) and PD1 expression (m, right) of hepatic CD4+ T cells from mice 
fed for 6 or 12 months with ND or CD-HFD (abundance of CD4 6 months: ND 
n = 17 mice; CD-HFD n = 10 mice; WD-HTF n = 7 mice; 12 months: ND n = 11 mice; 
CD-HFD n = 6 mice; WD-HTF n = 5 mice; PD1 expression in CD4+ T cells 6 months: 
ND n = 15 mice; CD-HFD n = 14 mice; WD-HTF n = 7 mice; 12 months: ND n = 10 
mice; CD-HFD n = 6 mice; WD-HTF n = 5 mice). n, H&E, CD8 and PD1 hepatic 
staining (top), and quantification of CD8+ cells and PD1+ cells by 
immunohistochemistry (bottom) from 32-week-old hURI-tetOFFhep and non-
transgenic littermate control mice (n = 6 mice/group). Arrowheads, specific 
positive-staining cells. Scale bar, 100 μm. o, Hepatic abundance of TCRγδ 
T cells from mice fed for 6 or 12 months with ND or CD-HFD (6 months ND n = 8 
mice; CD-HFD n = 6 mice; 12 months ND n = 8 mice; CD-HFD n = 6 mice). p, Left, 
quantification of hepatic Cd274+ expression by mRNA in situ hybridization of 
mice fed for 6 or 12 months with ND or CD-HFD (6 months: ND n = 6 mice;  
CD-HFD n = 6 mice; 12 months: ND n = 3 mice; CD-HFD n = 3 mice). Middle, 
quantification of hepatic PDL1+ expression by immunohistochemistry of mice 
fed for 12 months with ND or CD-HFD (ND n = 8 mice; CD-HFD n = 6 mice). Right, 
mRNA in situ hybridization (top) and PD1-stained micrographs (bottom). Scale 
bars, 100 μm. q, RNA velocity indicating transcriptional activity, gene 
expression, and the trajectory of CD8+ cells by scRNA-seq from 12 months ND 
or CD-HFD-fed mice. Root cells: yellow; blue cells: farthest away from root. End 
points: yellow indicates end point; blue cells: farthest away from defined end 
point. Latent time: pseudo-time by RNA velocity, dark color: start of velocity, 
yellow: end point of latent time. RNA velocity flow: Blue cluster: start point; 
orange cluster: intermediate; green: end point. Arrows: cell trajectory  
(n=3 mice/group). All data are shown as mean ± s.e.m. a, b, j–m, o, p, Two-tailed 
Student’s t-test. d–g, One-way ANOVA and Fisher’s LSD test. i, n, q, Two-tailed 
Mann–Whitney test.
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Extended Data Fig. 2 | Anti-PD1 treatment does not achieve anti-tumour 
effects in NASH-induced tumours. a, b, Synteny analysis of mouse HCC (a) 
and quantification of genomic aberrations by array-based comparative 
genomic hybridization (aCGH) for mice after 12 months on CD-HFD (n = 19) and 
for human NALFD/NASH–HCC (n = 78). The results here are in whole or part 
based upon data generated by the TCGA Research Network (https://www.
cancer.gov/tcga). c, MRI images of mouse liver after 13 months on CD-HFD 
followed by 7 weeks with or without treatment with anti-PD1 antibodies (n = 3 
mice per group). Dashed outlines indicate tumour nodules. Scale bars, 10 mm. 
d, Histological staining of hepatic tissue with H&E, Sirius Red, CD8 and PD1 of 
mice fed for 15 months ND or CD-HFD and either untreated or treated for 
8 weeks with anti-PD1 antibodies (H&E: ND n = 3 mice; CD-HFD n = 10 mice; CD-
HFD + anti-PD1 n = 8 mice; Sirius Red: ND n = 3 mice; CD-HFD n = 5 mice; CD-HFD 
+ anti-PD1 n = 9 mice; CD8, PD1: ND n = 3 mice; CD-HFD n = 13 mice; CD-HFD + 
anti-PD1 n = 8 mice). Scale bar, 50 μm. Arrowheads, CD8+ or PD1+ cells. e, NAS 
evaluation by H&E staining of hepatic tissue from mice fed for 15 months with 
ND or CD-HFD and either untreated or treated for 8 weeks with anti-PD1 
antibodies (ND n = 3 mice; CD-HFD n = 10 mice; CD-HFD + anti-PD1 n = 8 mice).  
f, ALT levels mice as in e (ND n = 3 mice; CD-HFD n = 4 mice; CD-HFD + anti-PD1 
n = 8 mice). g, Quantification of fibrosis by Sirius Red staining of hepatic tissue 
from mice as in e (ND n = 3 mice; CD-HFD n = 5 mice; CD-HFD + anti-PD1 n = 9 
mice). h, Quantification of tumour/lesion size and tumour load in livers from 
mice as in e (tumour/lesion size and tumour load: CD-HFD n = 9 mice; CD-HFD + 
anti-PD1 n = 7 mice; tumour incidence: CD-HFD n = 17 tumours/lesions in 22 
mice; CD-HFD + anti-PD1 n = 10 tumours/lesions in 10 mice). i, Staining for CD8 
and quantification of PD1+ cells in hepatic tissue by immunohistochemistry for 
mice as in e (ND n = 3 mice; CD-HFD n = 13 mice; CD-HFD + anti-PD1 n = 8 mice; 
intra-tumoral staining: CD-HFD n = 11 mice; CD-HFD + anti-PD1 n = 8 mice). Scale 
bar, 100 μm. j, k, Quantification and expression of PD1 in hepatic CD4+ and 
CD8+ T cells ( j) and polarization of CD8+ T cells (k) by flow cytometry for mice 
fed for 15 months with CD-HFD and either untreated or treated for 8 weeks with 
anti-PD1 antibodies (CD-HFD n = 4 mice; CD-HFD + anti-PD1 n = 8 mice).  
l, Quantification of hepatic PD1+ CD4+ and PD1+ CD8+ T cells by flow cytometry 
for mice as in j (CD-HFD n = 4 mice; CD-HFD + anti-PD1 n = 8 mice). m, n, 
Expression of Tnf (m) and Cxcr6 (n, left) in hepatic intra-tumoral and peri-
tumoral tissue from mice as in j with quantification of Cxcr6-expressing cells 
(n, right) (quantification of CXCR6: peri-tumoral: CD-HFD n = 15 fields of view 
(FOV) in 6 tumours from 2 mice; CD-HFD + anti-PD1 n = 10 FOV in 6 tumours 
from 2 mice; intra-tumoral: CD-HFD n = 17 FOV in 6 tumours from 2 mice;  
CD-HFD + anti-PD1 n = 17 FOV in 6 tumours from 2 mice). Scale bars, 100 μm. 
Arrowheads, positive cells. All data are shown as mean ± s.e.m. b, Mann–
Whitney test. e–g, One-way ANOVA and Fisher’s LSD test. h–l, n, Two-tailed 
Student’s t-test.
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Extended Data Fig. 3 | Anti-PDL1 treatment does not achieve anti-tumour 
effects in NASH-induced tumours, but in non-NASH livers PD1-targeted 
immunotherapy leads to prolonged survival. a, MRI images of livers of mice 
after 13 months CD-HFD either untreated or after 7 weeks of treatment with 
anti-PDL1 antibodies (CD-HFD n = 6 mice; CD-HFD + anti-PDL1 n = 8 mice). 
Dashed outlines indicate tumour nodules. Scale bar, 10 mm. b, Livers of mice 
fed with ND or CD-HFD for 13 months and either untreated or treated for 
8 weeks with anti-PDL1 antibodies. Arrowheads, tumours or lesions. Scale bar, 
10 mm. c, Body weight and ALT of mice as in b (ND n = 8 mice; CD-HFD n = 6 mice; 
CD-HFD + anti-PDL1 n = 6 mice). d, e, NAS evaluation by H&E, quantification of 
fibrosis by Sirius Red, and quantification of CD8, PD1 and PDL1 staining of 
hepatic tissue by immunohistochemistry (d) and corresponding micrographs 
(e) of mice fed for 13 months with ND or CD-HFD and untreated or treated for 
8 weeks with anti-PDL1 antibodies (NAS: ND n = 7 mice; CD-HFD n = 6 mice;  
CD-HFD + anti-PDL1 n = 6 mice; Sirius Red: ND n = 7 mice; CD-HFD n = 5 mice;  
CD-HFD + anti-PDL1 n = 6 mice; CD8: ND n = 5 mice; CD-HFD n = 5 mice; CD-HFD 
+ anti-PDL1 n = 5 mice; PD1 and PDL1: ND n = 5 mice; CD-HFD n = 5 mice; CD-HFD 
+ anti-PDL1 n = 6 mice). Scale bar, 100 μm. Arrowheads, positive cells. f, Tumour 
or lesion incidence in mice fed with CD-HFD for 15 months and untreated or 
treated for 8 weeks with anti-PDL1 antibodies (CD-HFD n = 19 tumours/lesions 
in 25 mice; CD-HFD + anti-PDL1 n = 7 tumours/lesions in 8 mice). g, Survival 
analysis of mice with hydrodynamically delivered NrasG12Vp19Arf−/− liver tumours 
with OVA as antigen, treated with isotype or anti-PD1 antibodies (control n = 8 
mice; anti-PD1 n = 10 mice). h, Survival analysis of a non-NASH model of HCC in 
which tumours are generated autochthonally in the liver by hydrodynamic 
injection of genetic elements (OVA, SIY, SIN and MYC-lucOS, in a CRISPR-based 
vector with tumour suppressor p53 deleted (sg-p53), and a transposase-
expressing vector (SB13)). Mice were treated on days 7, 9 and 11 with IgG or anti-
PD1 (control n = 6 mice; anti-PD1 n = 6 mice). i, Survival analysis of mice with  
RIL-175 Hras/P53-mutant hydrodynamically induced liver tumours, treated 
with IgG or anti-PD1 (n = 35 mice per group). All data are shown as mean ± s.e.m. 
c, d, One-way ANOVA and Fisher’s LSD test. f, Two-sided Fisher’s exact test.  
i, Two-tailed Student’s t-test. g–i, Two-sided χ2 test.
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Extended Data Fig. 4 | Preventive anti-PD1 treatment drives 
hepatocarcinogenesis in a CD8-dependent manner in NASH. a, Histological 
staining of hepatic tissue with H&E, Sirius Red and PD1 from mice fed for 
12 months with ND or CD-HFD and treated for 8 weeks with IgG, anti-CD8 or 
anti-PD1 antibodies (H&E: ND n = 24 mice; CD-HFD n = 40 mice; CD-HFD + anti-
CD8 n = 29 mice; CD-HFD + anti-PD1 n = 36 mice; Sirius Red: ND n = 19 mice; CD-
HFD n = 53 mice; CD-HFD + anti-CD8 n = 24 mice; CD-HFD + anti-PD1 n = 33 mice; 
PD1: ND n = 5 mice; CD-HFD n = 5 mice; CD-HFD + anti-CD8 n = 5 mice; CD-HFD + 
anti-PD1 n = 7 mice). Arrowheads, PD1+ cells. Scale bars, 50 μm. b–d, NAS 
evaluation by H&E (b), ALT levels (c) and histological staining of hepatic tissue 
by H&E and Sirius Red (d) of mice fed for 12 months with ND or CD-HFD, and 
untreated or treated for 8 weeks with anti-CD8 or anti-CD8 + anti-NK1.1 
antibodies (fibrosis ND n = 19 mice; CD-HFD n = 53 mice; CD-HFD + anti-CD8 
n = 27 mice; CD-HFD + anti-CD8/NK1.1 n = 6 mice; NAS: ND n = 24 mice; CD-HFD 
n = 40 mice; CD-HFD + anti-CD8 n = 29 mice; CD-HFD + anti-CD8/NK1.1 n = 6; 
ALT: ND n = 22 mice; CD-HFD n = 42 mice; CD-HFD + anti-CD8 n = 31 mice;  
CD-HFD + anti-CD8/NK1.1 n = 6). Scale bar, 100 μm. e, f, Flow cytometry plots  
of hepatic cells from mice fed for 12 months with ND or CD-HFD and treated  
for 8 weeks with anti-CD8 (e) or anti-CD8 + anti-NK1.1 (f) antibodies.  
g, Quantification by immunohistochemistry of PD1+ cells in hepatic tissue from 
mice fed for 12 months with ND or CD-HFD and untreated or treated for 8 weeks 
treatment with anti-CD8 or anti-PD1 antibodies (ND n = 5 mice; CD-HFD n = 5 
mice; CD-HFD + anti-CD8 n = 5 mice; CD-HFD + anti-PD1 n = 7 mice).  
h, Assessment of metabolic tolerance by intraperitoneal glucose tolerance test 
of mice as in g (CD-HFD n = 8 mice; CD-HFD + anti-CD8 n = 10 mice; CD-HFD + 
anti-PD1 n = 9 mice). i, Relative quantification of hepatic leukocytes of mice as 
in g (CD3, NK T: CD-HFD n = 9 mice; CD-HFD + anti-CD8 n = 14 mice; CD-HFD + 
anti-PD1 n = 8 mice; CD4, CD8, CD19, NK, CD11b+, mDC: CD-HFD n = 9 mice; CD-
HFD + anti-CD8 n = 17 mice; CD-HFD + anti-PD1 n = 8 mice; pDC: CD-HFD n = 9 
mice; CD-HFD + anti-CD8 n = 13 mice; CD-HFD + anti-PD1 n = 8 mice; Kupffer 
cells (KC): CD-HFD n = 9 mice; CD-HFD + anti-CD8 n = 12 mice; CD-HFD + anti-
PD1 n = 8 mice). More MHCII+ myeloid cells were found in the respective sub-
populations. j, Flow cytometry analysis for polarization of hepatic CD4+ T cells 
from mice as in g (CD-HFD n = 12 mice; CD-HFD + anti-CD8 n = 17 mice; CD-HFD + 
anti-PD1 n = 17 mice). k, Flow cytometric analysis for polarization of hepatic 
myeloid cells of mice fed for 12 months with CD-HFD and untreated or treated 
for 8 weeks with anti-PD1 antibodies (CD-HFD n = 8 mice; anti-PD1 + CD-HFD 
n = 12 mice). l, Flow cytometric analysis for polarization of hepatic CD8+ T cells 
from mice as in k (CD-HFD n = 10 mice; anti-PD1 + CD-HFD n = 14 mice).  
m, Confocal analyses revealed clusters of CD8+ T cells with adjacent cleaved 
caspase 3+ hepatocytes that were strongly increased by anti-PD1-related 
immunotherapy in liver tissue from mice fed for 12 months with ND or CD-HFD 
and treated for 8 weeks with IgG or anti-PD1 antibodies, suggesting increased 
necro-inflammation in the vicinity of CD8+ T cells (n = 27 FOV in 3 mice per 
group). Scale bars, 30 μm. n, GSEA of RNA-seq data for hepatic tissue from mice 
fed for 12 months with CD-HFD and treated for 8 weeks with anti-CD8, anti-
CD8 + anti-NK1.1 or anti-PD1 antibodies (n = 5 mice per group) revealed 
enrichment for TNF signalling via NF-κB and inflammatory responses. Deletion 
of NK1.1+ cells altered the cholesterol homeostasis-related signature, 
suggesting a link between NK T cells and aberrant cholesterol metabolism. 
Moreover, tissue from mice treated with anti-PD1 antibodies revealed positive 
enrichment of apoptosis, inflammatory responses and epithelial–
mesenchymal transition, indicating a pro-inflammatory, pro-carcinogenic 
liver environment upon anti-PD1 treatment. o, Livers from mice fed for 
12 months with CD-HFD and treated for 8 weeks with IgG or anti-PD1 antibodies. 
Arrowheads, tumours or lesions. Scale bar, 10 mm. All data are shown as 
mean ± s.e.m. b, c, One-way ANOVA and Fisher’s LSD test. h, Two-way ANOVA 
and Sidak’s multiple comparison test. i–l, Two-tailed Student’s t-test. m, Two-
tailed Mann–Whitney test.
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Extended Data Fig. 5 | Anti-PD1 treatment drives hepatocarcinogenesis by 
enhancing an inflammatory and pro-tumorigenic liver microenvironment. 
a, Histological staining with H&E and CD8 of hepatic tissue from wild-type or 
Pdcd1−/− mice fed for 6 months with ND or CD-HFD (H&E: ND n = 8 mice; Pdcd1−/− 
ND n = 5 mice; CD-HFD n = 9 mice; Pdcd1−/− CD-HFD n = 13 mice; CD8: ND n = 4 
mice; CD-HFD n = 5 mice; Pdcd1−/− CD-HFD n = 7 mice). Arrowheads, CD8+ cells. 
Scale bar, 50 μm. b, Cytokine expression of hepatic CD8+ T cells from mice as in 
a (ND n = 4 mice; Pdcd1−/− ND n = 5 mice; CD-HFD n = 5 mice; Pdcd1−/− CD-HFD n = 6 
mice). c, Tumour or lesion incidence in wild-type or Pdcd1−/− mice fed for 
6 months with CD-HFD (CD-HFD n = 6 tumours/lesions in 63 mice; Pdcd1−/−  
CD-HFD n = 6 tumours/lesions in 13 mice). d, ALT levels for mice as in a (ND n = 9 
mice; Pdcd1−/− ND n = 5 mice; CD-HFD n = 9 mice; Pdcd1−/− CD-HFD n = 10 mice).  
e, NAS evaluation by H&E of mice as in a (ND n = 8 mice; Pdcd1−/− ND n = 5 mice; 
CD-HFD n = 9 mice; Pdcd1−/− CD-HFD n = 13 mice). f, Quantification of CD8+ cells 
in hepatic tissue by immunohistochemistry of mice as in a (ND n = 4 mice; 
Pdcd1−/− ND n = 5 mice; CD-HFD n = 5 mice; Pdcd1−/− CD-HFD n = 7 mice).  
g, Relative quantification of hepatic leukocytes in mice as in a (ND n = 4 mice; 
Pdcd1−/− ND n = 5 mice; CD-HFD n = 5 mice; Pdcd1−/− CD-HFD n = 6 mice).  
h, Immune cancer field (ICF) and ICF patterns of RNA-seq data for hepatic 
tissue from mice fed for 12 months with ND or CD-HFD and treated for 8 weeks 
treatment with IgG, anti-PD1 or anti-CD8 antibodies (ND, CD-HFD + anti-PD1, 
CD-HFD + anti-CD8 n = 5 mice per group; CD-HFD n = 4 mice) through single-
sample GSEA. i, mRNA in situ hybridization (left) and quantification (right) for 
hepatic TNF+ cells from mice as in h (ND n = 25 FOV in 3 mice; CD-HFD n = 27 FOV 
in 3 mice; CD-HFD + anti-PD1 n = 40 FOV in 3 mice; CD-HFD + anti-CD8 n = 55 FOV 
in 3 mice). Arrowheads, TNF+ cells. Scale bar, 20 μm. j, GSEA of RNA-seq data for 
hepatic tissue comparing tumour-bearing mice fed for 12 months with CD-HFD 
and untreated or treated for 8 weeks with anti-PD1 antibodies (n = 5 mice per 
group). k, mRNA in situ hybridization (left) and quantification (right) for 
hepatic TNF+ cells from mice fed for 12 months with CD-HFD and untreated or 
treated for 8 weeks with anti-PD1 antibodies, with or without tumours (without 
tumours: CD-HFD n = 30 FOV in 3 mice; CD-HFD + anti-PD1 n = 40 FOV in 3 mice; 
peri-tumoural: CD-HFD n = 20 FOV in 3 mice; CD-HFD + anti-PD1 n = 21 FOV in 3 
mice; intra-tumoural: CD-HFD n = 19 FOV in 3 mice; CD-HFD + anti-PD1 n = 22 
FOV in 3 mice). Arrowheads, TNF+ cells. Scale bar, 20 μm. l, Quantification of 
CD8 staining by immunohistochemistry of peri- and intra-tumoural hepatic 
tissue from mice fed for 12 months with CD-HFD and untreated or treated for 
8 weeks with anti-PD1 antibodies (peri-tumoural: CD-HFD n = 11 mice; CD-HFD + 
anti-PD1 n = 10 mice; intra-tumoural: CD-HFD n = 5 mice; CD-HFD + anti-PD1 n = 7 
mice). m, Histological staining for p62 (right) and quantification (left) of liver 
tumour tissue from mice fed for 12 months with ND or CD-HFD and untreated or 
treated for 8 weeks with anti-PD1 antibodies or anti-CD8 antibodies (n = 5 mice 
per group). Scale bar, 100 μm. n, Genomic aberrations by array comparative 
genomic hybridization (aCGH) of tumour tissue from mice fed for 12 months 
with CD-HFD and untreated (n = 9) or treated for 8 weeks with anti-PD1 
antibodies (n = 12). All data are shown as mean ± s.e.m. b, d–i, m, One-way 
ANOVA and Fisher’s LSD test. c, Two-sided Fisher’s exact test. k, l, Two-tailed 
Student’s t-test.
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Extended Data Fig. 6 | CD8+PD1+ TOXhigh T cells with a resident-like character 
are enriched and are cellular drivers of hepatic necroinflammation and 
increased hepatocarcinogenesis upon anti-PD1 treatment in mice with 
NASH. a–c, scRNA-seq analysis of hepatic TCRβ+ cells (a), expression of 
selected markers in hepatic CD8+ T cells by scRNA-seq comparing CD8+ with 
CD8+PD1+ T cells (b), and average UMI comparison (c) of hepatic CD8+PD1+ 
T cells from mice fed for 12 months with CD-HFD and treated for 8 weeks with 
IgG, anti-PD1 antibodies or anti-CD8 antibodies (n = 3 mice per group).  
d, Velocity analyses on scRNA-seq data from CD8+ cells from mice fed for 
12 months with ND or CD-HFD and treated for 8 weeks with anti-PD1 antibodies 
(n = 3 mice). Yellow, root cells; yellow; blue, farthest from root. End points: 
yellow, end point cells; blue, farthest from defined end point. RNA velocity 
flow: blue cluster, start point; orange cluster, intermediate; green cluster, end 
point. Arrow shows trajectory of cells. e, Velocity analyses of scRNA-seq data 
showing correlation of expression of selected genes along the latent time of 
ND-fed mice (n = 3 mice). Latent time (pseudo-time by RNA velocity): dark 
colour, start of RNA velocity; yellow, end point of latent time. f, RNA velocity 
analyses by scRNA-seq indicating transcriptional activity and gene expression 
of CD8+ cells from mice fed for 12 months with ND or CD-HFD and untreated or 
treated for 8 weeks with anti-PD1 antibodies (n = 3 mice per group).  
g, Expression of selected markers in hepatic CD8+PD1+ T cells sorted from 
TCRβ+ cells by mass spectrometry from mice fed for 12 months with CD-HFD 
and untreated or treated for 8 weeks with anti-PD1 antibodies (n = 6 mice per 
group). h, Analyses of CD4+ and CD4+PD1+ T cells derived from livers of NASH 
mice with or without anti-PD1 treatment indicate minor differences in 
expression of selected markers in hepatic CD4+ T cells sorted from TCRβ+ cells 
by scRNA-seq comparing CD4+ with CD4+PD1+ T cells from mice fed for 
12 months with CD-HFD and treated for 8 weeks with IgG, anti-PD1 or anti-CD8 
antibodies (n = 3 mice per group). i, Comparison of average UMIs for hepatic 
CD4+ T cells from mice fed for 12 months with CD-HFD and treated for 8 weeks 
with IgG or anti-PD1 antibodies (n = 3 mice per group). j, Quantification of 
manual gating (left) and flow cytometry plots (right) for hepatic CD8+PD1+TNF+ 
cell abundance in mice as in i (CD-HFD n = 8 mice; CD-HFD + anti-PD1 n = 6 mice). 
k, CellCNN-analysed flow cytometry data for hepatic CD8+ T cells from  
mice as in i (CD-HFD + IgG n = 6 mice; CD-HFD + anti-PD1 n = 4 mice).  
l, Immunofluorescence staining for PD1, CD8 and Ki-67 of liver tissue from mice 
fed for 12 months with ND or CD-HFD and treated for 8 weeks with IgG or anti-
PD1 antibodies (n = 2 mice per group). Scale bar, 100 μm. m, In vitro stimulated 
splenic CD8 T cells from C57Bl/6 mice were treated with anti-PD1 antibody for 
72 h. Cell count (left), n = 5 experiments per group; Ki-67 (right), n = 4 
experiments per group. n–p, Quantification of intracellular FOXO1 (n), calcium 
levels (o), and polarization (p) in CD8+ T cells isolated by flow cytometry from 
mice fed for 12 months with ND or CD-HFD and untreated or treated for 8 weeks 
with anti-PD1 antibodies (FOXO1: ND n = 6 mice; CD-HFD n = 5 mice; CD-HFD + 
anti-PD1 n = 7 mice; calcium: ND n = 13 mice; CD-HFD n = 10 mice; CD-HFD + anti-
PD1 n = 10 mice; polarization: ND n = 6 mice; CD-HFD n = 5 mice; CD-HFD + anti-
PD1 n = 6 mice). q, Relative quantification by flow cytometry of hepatic 
CD8+PD1+ cells from mice as in n (ND n = 6 mice; CD-HFD n = 5 mice; CD-HFD + 
anti-PD1 n = 6 mice). r–t, Quantification of intracellular calcium (r), FOXO1 (s) 
and polarization (t) in CD4+ T cells isolated by flow cytometry from mice as in n 
(FOXO1: ND n = 6 mice; CD-HFD n = 5 mice; CD-HFD + anti-PD1 n = 7 mice; 
calcium: ND n = 13 mice; CD-HFD n = 10 mice; CD-HFD + anti-PD1 n = 10 mice; 
polarization: ND n = 6 mice; CD-HFD n = 5 mice; CD-HFD + anti-PD1 n = 6 mice).  
u, Relative quantification by flow cytometry of hepatic CD4+PD1+ T cells from 
mice as in n (ND n = 6 mice; CD-HFD n = 5 mice; CD-HFD + anti-PD1 n = 6 mice).  
All data are shown as mean ± s.e.m. f, Two-tailed Mann–Whitney test. j, m, Two-
tailed Student’s t-test. n–u, Two-way ANOVA and Fisher’s LSD test.
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Extended Data Fig. 7 | CD8+ T cells drive hepatic inflammation and 
subsequent liver cancer in a TNF-dependent manner upon PD1-targeted 
immunotherapy. a, b, Histological evaluation (a) and representative 
micrographs (b) of Sirius Red, CD4, CD8, PD1, PDL1, F4/80, and MHC-II staining 
of mice fed for 12months with ND or CD-HFD and untreated or treated for 
8 weeks with anti-PD1, anti-PD1 + anti-CD8, anti-TNF, anti-PD1 + anti-TNF, anti-
CD4 or anti-PD1 + anti-CD4 antibodies (Sirius Red: ND n = 11 mice; CD-HFD n = 12 
mice; CD-HFD + anti-PD1 n = 12 mice; CD-HFD + anti-PD1 + anti-CD8 n = 9 mice; 
CD-HFD + anti-TNF n = 10 mice; CD-HFD + anti-PD1 + anti-TNF n = 11 mice; CD-
HFD + anti-CD4 n = 8 mice; CD-HFD + anti-PD1 + anti-CD4 n = 8 mice; CD4: ND 
n = 10 mice; CD-HFD n = 11 mice; CD-HFD + anti-PD1 n = 14 mice; CD-HFD + anti-
PD1 + anti-CD8 n = 9 mice; CD-HFD + anti-TNF n = 10 mice; CD-HFD + anti-
PD1 + anti-TNF n = 11 mice; CD-HFD + anti-CD4 n = 8 mice; CD-HFD + anti-
PD1 + anti-CD4 n = 8 mice; CD8: ND n = 10 mice; CD-HFD n = 12 mice; CD-HFD + 
anti-PD1 n = 14 mice; CD-HFD + anti-PD1 n = 14 mice; CD-HFD + anti-PD1 + anti-
CD8 n = 9 mice; CD-HFD + anti-TNF n = 10 mice; CD-HFD + anti-PD1 + anti-TNF 
n = 11 mice; CD-HFD + anti-CD4 n = 8 mice; CD-HFD + anti-PD1 + anti-CD4 n = 8 
mice; PD1: ND n = 12 mice; CD-HFD n = 12 mice; CD-HFD + anti-PD1 n = 14 mice; 
CD-HFD + anti-PD1 + anti-CD8 n = 8 mice; CD-HFD + anti-TNF n = 10 mice; CD-
HFD + anti-PD1 + anti-TNF n = 10 mice; CD-HFD + anti-CD4 n = 8 mice; CD-HFD + 
anti-PD1 + anti-CD4 n = 8 mice; PDL1: ND n = 10 mice; CD-HFD n = 11 mice; CD-
HFD + anti-PD1 n = 14 mice; CD-HFD + anti-PD1 + anti-CD8 n = 9 mice; CD-HFD + 
anti-TNF n = 10 mice; CD-HFD + anti-PD1 + anti-TNF n = 11 mice; CD-HFD + anti-
CD4 n = 8 mice; CD-HFD + anti-PD1 + anti-CD4 n = 8 mice; F4/80: ND n = 11 mice; 
CD-HFD n = 12 mice; CD-HFD + anti-PD1 n = 14 mice; CD-HFD + anti-PD1 n = 14 
mice; CD-HFD + anti-PD1 + anti-CD8 n = 9 mice; CD-HFD + anti-TNF n = 10 mice; 
CD-HFD + anti-PD1 + anti-TNF n = 11 mice; CD-HFD + anti-CD4 n = 8 mice; CD-
HFD + anti-PD1 + anti-CD4 n = 8 mice; MHC-II: ND n = 11 mice; CD-HFD n = 13 
mice; CD-HFD + anti-PD1 n = 14 mice; CD-HFD + anti-PD1 n = 14 mice; CD-HFD + 
anti-PD1 + anti-CD8 n = 9 mice; CD-HFD + anti-TNF n = 10 mice; CD-HFD + anti-
PD1 + anti-TNF n = 11 mice CD-HFD + anti-CD4 n = 8 mice; CD-HFD + anti-
PD1 + anti-CD4 n = 8 mice). Scale bar, 100 μm. c, d, ALT (c) and quantification (d) 
of hepatic CD8+PD-1+TNF+ T cells from mice fed for 12 months with ND or CD-
HFD and untreated or treated for 8 weeks with anti-PD-1, anti-PD-1 + anti-CD8, 
anti-TNF, anti-PD-1 + anti-TNF, anti-CD4, or anti-PD-1 + anti-CD4 antibodies 
(ALT: ND n = 30 mice; CD-HFD n = 47 mice; CD-HFD + anti-PD-1 n = 35 mice; CD-
HFD + anti-PD-1 + anti-CD8 n = 9 mice; CD-HFD + anti-TNF n = 10 mice; CD-HFD + 
anti-PD-1 + anti-TNF n = 11 mice; CD-HFD + anti-CD4 n = 8 mice; CD-HFD + anti-
PD-1 + anti-CD4 n = 8 mice; CD8+PD-1+TNF+: ND n = 8 mice; CD-HFD n = 5 mice; 
CD-HFD + anti-PD-1 n = 3 mice; CD-HFD + anti-PD-1 + anti-CD8 n = 9 mice; CD-
HFD + anti-TNF n = 10 mice; CD-HFD + anti-PD-1 + anti-TNF n = 11 mice; CD-HFD + 
anti-CD4 n = 8 mice; CD-HFD + anti-PD-1 + anti-CD4 n = 8 mice). All data are 
shown as mean ± s.e.m. All data were analysed by one-way ANOVA and Fisher’s 
LSD test.
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Extended Data Fig. 8 | PD1-targeted immunotherapy induces hepatic 
inflammation, which drives hepatocarcinogenesis in a CD8+ T cell-
dependent manner. a, b, Tumour or lesion load (a) and tumour or lesion size 
(b) in mice fed for 12 months with CD-HFD and untreated or treated for 8 weeks 
with anti-PD1, anti-PD1 + anti-CD8, anti-TNF, anti-PD1 + anti-TNF, anti-CD4, or 
anti-PD1 + anti-CD4 antibodies (CD-HFD n = 19 mice; CD-HFD + anti-PD1 n = 29 
mice; CD-HFD + anti-PD1 + anti-CD8 n = 2 mice; CD-HFD + anti-TNF n = 3 mice; 
CD-HFD + anti-PD1 + anti-TNF n = 3 mice; CD-HFD + anti-CD4 n = 3 mice; CD-HFD 
+ anti-PD1 + anti-CD4 n = 8 mice). c, d, UMAP representation of 63 parameters 
(serology, flow cytometry, histology) (c) and selected displays of analysed 
parameters (d) indicating the severity of NASH pathology in mice fed for 
12 months with ND or CD-HFD and untreated or treated for 8 weeks with anti-
CD8, anti-CD8 + anti-NK1.1, anti-PD1, anti-PD1 + anti-CD8, anti-TNF, anti-
PD1 + anti-TNF, anti-CD4, or anti-PD1 + anti-CD4 antibodies (ND n = 22 mice;  
CD-HFD n = 31 mice; CD-HFD + anti-PD1 n = 41 mice; CD-HFD + anti-PDL1 n = 6 
mice; CD-HFD + anti-CD8 n = 24 mice; CD-HFD + anti-CD8 + anti-NK1.1 n = 6 
mice; CD-HFD + anti-PD1 + anti-CD8 n = 9 mice; CD-HFD + anti-TNF n = 10 mice; 
CD-HFD + anti-PD1 + anti-TNF n = 11 mice; CD-HFD + anti-CD4 n = 9 mice;  
CD-HFD + anti-PD1 + anti-CD4 n = 9 mice). e, Data gathered from hepatic tissue 
analyses were binary correlated with one another for mice fed for 6 or 
12 months with ND or CD-HFD and treated for 8 weeks with anti-CD8, anti-
CD8 + anti-NK1.1, anti-PD1, anti-PD1 + anti-CD8, anti-TNF, anti-PD1 + anti-TNF, 
anti-CD4, or anti-PD1 + anti-CD4 antibodies (ND n = 47 mice; CD-HFD n = 72 
mice; CD-HFD + anti-PD1 n = 41 mice; CD-HFD + anti-PDL1 n = 6 mice; CD-HFD + 
anti-CD8 n = 29 mice; CD-HFD + anti-CD8 + NK1.1 n = 6 mice; CD-HFD + anti-
PD1 + anti-CD8 n = 9 mice; CD-HFD + anti-TNF n = 10 mice; CD-HFD + anti-
PD1 + anti-TNF n = 11 mice; CD-HFD + anti-CD4 n = 9 mice; CD-HFD + anti-
PD1 + anti-CD4 n = 9 mice). All data are shown as mean ± s.e.m. a, b, One-way 
ANOVA and Dunn’s multiple comparison test. e, Two-tailed Spearman’s 
correlation.
Extended Data Fig. 9 | See next page for caption.
Article
Extended Data Fig. 9 | An inflammatory cellular polarization of T cells can 
be found in liver biopsies from patients with NAFLD or NASH. a, b, Flow 
cytometry plots and quantification of patient-liver-derived PD1+CD8+ T cells 
(a), and correlation of PD1+CD8+ T cells with BMI, NAS and ALT for healthy 
participants and patients with NAFLD or NASH (b) (Supplementary Table 1; 
healthy controls n = 8; NAFLD/NASH n = 16 patients). c–e, Flow cytometry plot 
of FMO control (c), quantification of patient-liver-derived PD1+CD8+ T cells (d), 
and quantification of CD4, CD8, γδ, NK and NK T cells from healthy participants 
or patients with NAFLD or NASH (e) (Supplementary Table 1: healthy controls 
n = 8; NAFLD/NASH n = 16 patients). f, g, Heat map showing median marker 
expression (f) and quantification of the defined CD45+ subsets from Fig. 3c (g) 
by flow cytometry derived from hepatic biopsies from control participants and 
patients with NAFLD or NASH to define distinct marker expression 
(Supplementary Table 2: control individuals n = 6; NAFLD/NASH n = 11 patients). 
h–j, HSNE representation of defined T cell subsets (h), marker expression (i) 
and quantification of CD8+CD103+PD1+ cells ( j) in liver-derived T cells from 
control individuals and patients with NAFLD or NASH analysed by cytometry by 
time of flight (CyTOF) (control n = 11 individuals pooled in 3 analyses; NAFLD/
NASH n = 16 patients pooled in 5 analyses). k, l, Selected average marker 
expression in CD4+ and CD8+ T cell subsets (k) and differential gene expression 
of CD8+PD1+ versus CD8+ T cells and CD4+PD1+ versus CD4+ T cells by scRNA-seq 
(l) for control individuals and patients with NAFLD or NASH (control n = 4 
individuals; NAFLD/NASH n = 7 patients). All data are shown as mean ± s.e.m. All 
data were analysed by two-tailed Mann–Whitney test.
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Extended Data Fig. 10 | PD1 and PDL1 targeted immunotherapy in advanced 
HCC has a distinct effect depending on disease aetiology. a, Comparison of 
RNA-seq data from patients with NASH with varying degrees of fibrosis (F0–F4, 
Brunt classification) normalized to data from patients with NAFLD from a total 
of n = 206 patients with NAFLD or NASH. b, c, Immunohistochemical staining 
(b) and quantification (c) of hepatic PD1+, CD8+, and CD4+ cells from patients 
with NAFLD or NASH with varying degrees of fibrosis (Supplementary Table 3) 
(NAFLD n = 9 patients; NASH F0/1 n = 7 patients; NASH F2 n = 12 patients; NASH 
F3 n = 21 patients; NASH F4 n = 16 patients; CD4: NAFL n = 6 patients; NASH F0/1 
n = 4 patients; NASH F2 n = 8 patients; NASH F3 n = 17 patients; NASH F4 n = 9 
patients). Scale bar, 100 μm. d, Correlation analysis of PD1 expression against 
fibrosis grade by immunohistochemical staining (NAFLD/NASH n = 65 
patients). e, Immunohistochemical staining and quantification of ratio of PD1+/
CD8+ cells in immunohistochemical staining of samples from patient cohort in 
Supplementary Tables 4–6 (healthy individuals n = 4, NASH n = 26 patients, 
peri-tumoural NASH–HCC n = 16 patients, peri-tumoural HCC other aetiologies 
n = 29 patients). Scale bar, 100 μm. f, Immunohistochemical staining and 
quantification of PD1+ cells and MIB1+ hepatocytes in peri-tumoural and intra-
tumoural samples from patients with HCV- or NASH-induced HCC (PD1: peri-
tumoural HCV n = 16 tissues from 7 patients; peri-tumoural NASH n = 9 tissues 
from 2 patients; intra-tumoural HCV n = 10 HCCs from 7 patients; intra-
tumoural NASH n = 6 HCCs from 2 patients; MIB1: peri-tumoural HCV n = 16 
tissues from 7 patients; peri-tumoural NASH n = 9 tissues from 2 patients; intra-
tumoural HCV n = 10 HCCs from 7 patients; intra-tumoural NASH n = 6 HCCs 
from 2 patients). Arrowheads, PD1+ or MIB1+ cells. Scale bars, 100 μm. g, PRISMA 
flow chart of the systematic review of targeted immunotherapy in HCC and the 
selection of articles assessing the clinical outcome of immune checkpoint 
inhibitors in advanced HCC for inclusion in the systematic review and meta-
analysis. ICPI, immune checkpoint inhibitor. A total of 1,243 patients were 
included in two first-line trials comparing PD1- or PDL1-targeted 
immunotherapy to sorafenib. In these trials, 707 patients received an immune 
checkpoint inhibitor (either anti-PD1 or anti-PDL1). h–j, HCV and HBV were 
pooled into a separate category, termed ‘viral’, and a subsequent meta-analysis 
comparing viral (n = 754) and non-viral HCC (n = 489; mostly NASH and alcohol 
intake) was performed (h). A subgroup analysis studying the specific effects of 
non-viral aetiologies (n = 489) on the magnitude of effect of immunotherapy is 
presented, when compared to HBV (i; n = 473) or HCV ( j; n = 281). HRs for each 
trial are represented by squares; the size of the square represents the weight of 
the trial in the meta-analysis. The horizontal line crossing the square 
represents the 95% CI. The diamonds represent the estimated overall effect 
based on the meta-analysis random effect of all trials. Inverse variance (IV) and 
random effects methods (Random) were used to calculate HRs, 95% CIs,  
P values, and the test for overall effect; these calculations were two-sided. 
Cochran’s Q-test and I2 were used to calculate heterogeneity. All data are shown 
as mean ± s.e.m. c, e, f, One-way ANOVA and Dunn’s multiple comparison test. 
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection Data were collected with Microsoft Excel.
Data analysis Flowcytometry: Cells were analyzed using BD FACSFortessa or BD FACSSymphony and data were analyzed using FlowJo (v10.6.2). For 
sorting, FACS Aria II and FACSAria FUSION in collaboration with the DKFZ FACS core facility were used. For UMAP/FlowSOM plots, BD 
FACSymphony data (mouse and human) were exported from FlowJo (v10). Analyses was performed as described elsewhere46.  
scRNA-seq (mouse): Single-cell capturing for scRNA-seq and library preparation was described previously47. Libraries (pooled at 
equimolar concentration) were sequenced on an Illumina NextSeq 500 at a median sequencing depth of ~40,000 reads/cell. Sequences 
were mapped to the mouse (mm10), using HISAT (version 0.1.6); reads with multiple mapping positions were excluded. Reads were 
associated with genes if they were mapped to an exon, using the Ensembl gene annotation database (Embl release 90). Exons of different 
genes that shared a genomic position on the same strand were considered as a single gene with a concatenated gene symbol. The level 
of spurious UMIs in the data was estimated by using statistics on empty MARS-seq wells and excluded rare cases with estimated noise > 
5% (median estimated noise overall experiments was 2%). Removal of specific mitochondrial genes, immunoglobulin genes, genes linked 
with poorly supported transcriptional models (annotated with the prefix “Rp-”), and cells with less than 400UMIs. Gene features were 
selected using Tvm=0.3 and a minimum total UMI count > 50. Hierarchical clustering of the correlation matrix between those genes 
(filtering genes with low coverage and computing correlation using a down-sampled UMI matrix) and selected the gene clusters that 
contained anchor genes. We used K=50, 750 bootstrap iterations, and otherwise standard parameters. Subsets of T-cells were obtained 
by hierarchical clustering of the confusion matrix and supervised analysis of enriched genes in homogeneous groups of metacells48.  
scRNA-seq (human): De-multiplexing and barcode processing was performed using the Cell Ranger Software Suite (Version 4.0.0) and 
reads were aligned to human GRCh3863. Gene-barcode matrix containing cell barcodes and gene expression counts was generated by 
counting the single-cell 3’ UMIs, imported into R (v4.0.2) where quality control and normalization were executed using Seurat v364. Cells 
with more than 10% mitochondrial genes, fewer than 200 genes per cell, or more than 6000 genes per cell were excluded. Matrices from 
10 samples were integrated with Seurat v3 to remove batch effects across samples. PCA analysis of filtered gene-barcode matrices of all 
CD3+ cells, visualized by UMAP (top 50 principal components) and identification of major cell types using the highly variable features and 
indicative markers was performed. Besides, pairwise combinations of CD4+ T-cells vs CD4+PD-1+ T-cells and CD8+ T-cells vs CD8+PD-1+ 






















Volcano plots were then generated using EnhancedVolcano (v1.6.0)66 to visualize the results of differential expression analysis.  
Velocity and correlation analyses of scRNA-seq data: Velocyto (0.6) was used to estimate the spliced/unspliced counts from the pre-
aligned bam files49. RNA velocity, latent time, root, and terminal states were calculated using the dynamical velocity model from scvelo 
(0.2.2)50. Kendall’s rank correlation coefficient was used to correlate the expression patterns of biologically significant genes with latent 
time. 
Mass spectrometry: Analyses was performed using MaxQuant (1.6.7.0), mouse UniProt Isoform fasta (Version: 2019-02-21, number of 
sequences 25,233) as a source for protein sequences. 1% FDR was used for controlling at the peptide and protein level, with a minimum 
of two peptides needed for consideration of analysis. Gene set enrichment analysis was performed using ClusterProfiler (3.18)51 and 
gene sets obtained from WikiPathway (wikipathways.org) and MSigDB (broadinstitute.org/msigdb)52–54. 
Isolation of RNA and library preparation for bulk RNA sequencing: RNA isolation23and library preparation for bulk 3’-sequencing of 
poly(A)-RNA was described previously55. Using the with the Feature Extraction software (11.0.1.1, Agilent Technologies), gencode gene 
annotations version M18 and the mouse reference genome major release GRCm38 were derived from (https://
www.gencodegenes.org/). Dropseq tools v1.1256 were used for mapping the raw sequencing data to the reference genome. Resulting 
UMI filtered count matrix was imported into R v3.4.4. Prior differential expression analysis with Limma v3.40.657 sample-specific weights 
were estimated and used as coefficients alongside the experimental groups as a covariate during model fitting with Voom. T-test was 
used for determining differentially (p-value below 0.05) regulated genes between all possible experimental groups. Gene set enrichment 
analysis was conducted with the pre-ranked GSEA method53 within the MSigDB Reactome, KEGG, and Hallmark databases 
(broadinstitute.org/msigdb). Raw sequencing data are available under the accession number PRJEB36747.  
Mass cytometry: The sample was acquired on a Helios mass cytometer and raw data were EQ-Bead-normalized using Helios mass 
cytometer and Helios instrument software (version 6.7). Compensation was performed in CATALYST (v1.86)70 and FlowCore (1.50.0). De-
barcoding and gating of single, live CD45+ cells were performed using FlowJo (v10.6.2). Then, data of CD45+ cells were imported into 
Cytosplore 2.3.1 and transformed using the arcsinh(5) function. Major immune cell lineages were identified at the first level of a 2-level 
hierarchical stochastic neighbor embedding (HSNE) analysis with default perplexity and iteration settings. HSNE with the same 
parameters was run on CD3+ cells to identify T-cell phenotypes. Gaussian mean shift clustering was performed in Cytosplore and a 
heatmap of arcsinh(5)-transformed expression values of all antibody targets was generated. Cell type identification was based on the 
transformed expression values and clusters showing high similarity were merged manually. 
Search strategy, selection criteria, and meta-analysis of phase III clinical trials: The literature search was done through MEDLINE on 
PubMed, Cochrane Library, Web of Science, and clinicaltrials.gov, using the following searches: “checkpoint inhibitors”, ”HCC”, “phase 
III”, between January 2010 and January 2020, and complemented by hand searches of conference abstracts/presentations. Single-center, 
non-controlled trials, studies with insufficient data to extract hazard ratios (HR), 95% confidence intervals, or trials including disease 
entities other than HCC were excluded. As conference abstracts were not excluded, quality assessment of the included studies was not 
performed. Three studies5,13,14 fulfilled the criteria and were included in the quantitative synthesis (Extended Data 10). The primary 
outcome of the meta-analysis was OS, defined as the time from randomization to death. HRs and CIs related to OS were extracted from 
the papers/conference presentations5,13,14. Pooled HRs were calculated using the random-effects model (Der Simonian and Laird), and 
the generic inverse variance was used for calculating weights72. To evaluate heterogeneity among studies, Cochran’s Q test and I2 index 
were used. A p-value < 0.10 in the Q-test was considered to indicate substantial heterogeneity. I2 was interpreted as suggested in the 
literature: 0% to 40% might not represent significant heterogeneity; 30% to 60% may represent moderate heterogeneity, 50% to 90% 
may represent substantial heterogeneity, 75% to 100% represents considerable heterogeneity. All statistical pooled analyses were 
performed using the RevMan 5.3 software. 
Statistical analyses: Data was collected in Microsoft Excel. Mouse data are presented as the mean±SEM. Pilot experiments and previously 
published results were used to estimate the sample size, such that appropriate statistical tests could yield significant results. Statistical 
analysis was performed using GraphPad Prism software version 7.03 (GraphPad Software). Exact p-values lower than p< 0.1 are reported 
and specific tests are indicated in the legends. Survival analyses were performed using IBM SPSS Statistics version 25 (SPSS Inc., Chicago, 
IL).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The proteomics data described in this article is available at ProteomeXchange Consortium via the PRIDE under the identifier XD017236 login/password: /37ScigLe. 
The bulk-RNA-seq data described in this article is available at PRJEB36747. The single-cell RNA-seq data described in this article is available at GEO Submission 
(GSE144635). The array of comparative genomic hybridization data described in this article is available at GEO Submission (GSE144875). The results here are in 
whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. The human single-cell RNA-seq data described in this 
article is available at GEO Submission (GSE159977). Databases used in this manuscript are WikiPathways (wikipathways.org), MSigDB (www.broadinstitute.org/
msigdb). 
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Pilot experiments and previous published results were used to estimate the sample size such that appropriate statistical tests could yield 
significant results (DOI: 10.1016/j.ccell.2014.09.003; DOI: 10.1038/s41591-019-0379-5). The exact n numbers used in the study are indicated 
in the source data file.
Data exclusions No data exlusion of mice and human.
Replication All experiments presented were conducted with sufficient mouse numbers to ensure statistical significance could be reached, particularly for 
experiments involving tumor studies. 
Biochemical or image based data were reproduced in multiple mice: e.g. Weight analysis of mice, Measuring transaminase levels, NASH 
phenotype characterization, HCC development characterization, flow cytometry analyses, immunohistochemical staining, confocal analysis. 
All attempts of replicating data were successfull.
Randomization 5-week-old C57Bl/6 mice were randomly allocated into different groups and were fed with appropriated diet or treatment regimens. 
No prospective trial was performed, therefore randomization of human specimen was not relevant for the performed experiments.
Blinding Experiments with different genotypes on the same diet were blinded.  
For the dissection between ND or NASH mouse experiments this was not possible since the type of diet and the systemic obesity were visible 
to the researcher, e.g., the color of the normal diet is brown and color of the NASH-diet is green. 
The analysis of the transaminase level was blinded and measured with code labeling. The NASH phenotype analysis was blinded - still the 
morphology of the normal/chow-fed liver is different from a NASH liver.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems













Antibodies used Description of all antibodies (clone and supplier) used in the study are provided in the Materials&Methods Table 11-15. 
Validation Validation of commercial antibodies was done on a regular quality control of each lot by the manufacturer (e.g. Biolegend "The 
antibody was purified by affinity chromatography and conjugated with PE under optimal conditions."; "Each 
lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis."; "Every lot of product 
is quality tested against a "gold standard" reference lot. A new lot is only released based on our defined QC specifications to 
ensure lot to lot reproducibility and reliability. BioLegend guarantees the stability and performance of all our products shipped at 
room temperature". or Bioxcell for in vivo treatment antibodies "Binding Validation: Western Blot data shown below confirms 
that htis clone binds to its target antigen"). 
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals All animals are described in the Supplementary Materials. 
All mice were male and on a C57Bl/6 background and were put from 5-8 weeks of age onwards in the respective 
diets and/or treatment regimens. 
Following strains were used for the experiment described in the manuscript: C57Bl6/J and Pdcd1-/-.






















Field-collected samples not used
Ethics oversight Regierungspräsidium Karlsruhe, Karlsruhe, Germany
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics Human characteristics are reported in Supplementary Materials Table 1-10.
Recruitment No active recruitment was done in the frame of this study Baseline characteristics of analyzed human specimen are listed in 
Supplementary Tables 1-10. 
The human survival analyses are  retrospective studies, they need prospective validation.
Ethics oversight The respective ethics committee is listed in the Material&Method section. 
Flow cytometry of patient material (Figure 3a,b ) was performed under ethics oversight: BIOFACS Study KEK 2019-00114. 
Flow cytometry of human samples (Extended Data 9d) was approved by the local ethical committee (AC-2014-2094 n 03). 
High-throughput RNA sequencing of human specimen: As previously reported, RNA sequencing analysis was performed using the 
data from 206 snap-frozen biopsy samples from 206 patients diagnosed with NAFLD in France, Germany, Italy, and the UK and 
enrolled in the European NAFLD Registry (GSE135251)58,59. Collection and use of data of the European NAFLD Registry were 
approved by the relevant local and/or national Ethical Review Committee58. 
Isolation of cells for single-cell RNA-seq data analysis (human): Analyses of liver samples from patients undergoing bariatric 
surgery at the Department of Surgery at Heidelberg University Hospital (S-629/2013). 
Histological and immunohistochemical analysis of NASH/HCC cohort: All samples were obtained from International Genomic HCC 
Consortium with IRB approval. 
A cohort of patients with HCC treated with PD-(L)1-targeted immunotherapy: The retrospective analysis was approved by local 
Ethics Committees. Data from this cohort were published previously73. 
Validation cohort: Ethical approval to conduct this study was granted by the Imperial College Tissue Bank (Reference Number 
R16008). 
Analysis of human samples from the Department of Pathology and Molecular Pathology, University Hospital Zurich, was 
approved by the local ethics committee (‘Kantonale Ethikkommission Zürich’, KEK-ZH-Nr. 2013-0382 and BASEC-Nr. 
PB_2018-00252).
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Clinical data
Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration This study was performed not in active clinical trials.
Study protocol This study was performed not in active clinical trials.
Data collection The respective data collection (fresh/retrospective cohort analysis/analyses of published data) process is listed in the 
Material&Method section.




The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Please see Supplementary Materials. 
Mice were transcardially perfused with PBS, and livers were dissected. Livers were incubated for up to 35min in 37°C with 
digestion buffer (Collagen IV 1:10 (60 U f.c.) and DNase I 1:100 (25µg/ml f.c.)) and subsequently passed through a 100µm filter. 
Livers were washed with RPMI1640 (#11875093) medium and subsequently centrifuged for 7min/300g/4°C. Lymphocyte 
enrichment was achieved by a 2-step Percoll gradient (20ml 25% Percoll/HBSS underlay with 20ml 50% Percoll/HBSS) and 






















C, counted and transferred to a 15ml Falcon for a final washing step with FACS buffer (PBS supplemented with v/v 0.4% 0.5M 
EDTA pH= 8 and w/v 0.5% albumin fraction V (#90604-29-8)). Isolation of splenic lymphocytes was done by passing spleens 
through a 100µm mesh and subsequent washing. Afterwards, an erythrocyte lysis using ACK-buffer 1x 2ml for 5 min RT and then 
a wash was performed. For T-cell re-stimulation, cells were incubated for 2h, 37°C, 5% CO2 in RPMI 1640 supplemented with v/v 
2% fetal calf serum using 1:500 Biolegend´s Cell Activation Cocktail (with Brefeldin A) (#423304) and 1:1000 Monensin Solution 
(1,000X) (#420701). Staining was performed using Live/Dead discrimination by using DAPI or ZombieDyeNIR according to the 
manufacturer´s instructions. After washing (~400g, 5min, 4°C), cells were stained in 25µl of titrated antibody master mix for 
20min at 4°C and washed again (antibodies shown in Table 7-9). Samples for flow cytometric activated cell sorting (FACS) were 
then sorted. Samples for flow cytometry were fixed using eBioscience IC fixation (#00-8222-49) or Foxp3 Fix/Perm kit 
(#00-5523-00) according to the manufacturer´s instruction. Intracellular staining was performed in eBioscience Perm buffer 
(#00-8333-56). Cells were analyzed using BD FACSFortessa or BD FACSSymphony and data were analyzed using FlowJo. For 
sorting, a FACS Aria II and a FACSAria FUSION in collaboration with the DKFZ FACS core facility were used.  
Analysis of human material (Table 1) was performed on human liver tissue samples (needle biopsies or resected tissue, BIOFACS 
Study KEK 2019-00114), that were processed within 4 hours after collection. Tissue samples were minced using scalpels, 
incubated (1 mg/mL collagenase IV (Sigma Aldrich), 0.25 μg/mL DNase (Sigma Aldrich), 10% FCS (Thermo Fisher Scientific), RPMI 
1640 (Seraglob)) for 30 min at 37oC with continuous shaking. The enzymatic reaction was stopped with 2 mM EDTA (StemCell 
Technologies, Inc) in PBS. The homogenized cell suspension was filtered through 100 μm cell strainer and centrifuged to get a 
cell pellet. Next cells were resuspended in FACS Buffer (PBS, EDTA 2mM, FCS 0.5%) with Human TruStain FcX™ (Fc Receptor 
Blocking Solution) (Biolegend) and incubated for 15 min at 4oC. After cells were spun without washing and stained with the flow 
cytometry antibodies mix and Zombie Aqua™ Fixable Viability Kit (Biolegend).  
Instrument Cells were analyzed using BD FACSFortessa or BD FACSSymphony. For sorting, a FACS Aria II and a FACSAria FUSION in 
collaboration with the DKFZ FACS core facility were used. 
Software Collected data was analyzed by FlowJo V10.2.
Cell population abundance Absolute quantification by using CountBright™ Absolute Counting Beads.
Gating strategy Debry esclusion byFSC-A/SSC-A. Doublets were excluded by using FSC-A/ 
FSC-H and SSC-A/SSC-H gates. Life/Dead exclusion was performed. Remaining cells were analyzed according to displayed 
markers.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
